+

WO1997035194A2 - Procede de criblage enantiomere et compositions pour ce procede - Google Patents

Procede de criblage enantiomere et compositions pour ce procede Download PDF

Info

Publication number
WO1997035194A2
WO1997035194A2 PCT/US1997/004176 US9704176W WO9735194A2 WO 1997035194 A2 WO1997035194 A2 WO 1997035194A2 US 9704176 W US9704176 W US 9704176W WO 9735194 A2 WO9735194 A2 WO 9735194A2
Authority
WO
WIPO (PCT)
Prior art keywords
library
peptide
protein
domains
target
Prior art date
Application number
PCT/US1997/004176
Other languages
English (en)
Other versions
WO1997035194A3 (fr
Inventor
Anthony C. Forster
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Priority to AU25313/97A priority Critical patent/AU2531397A/en
Publication of WO1997035194A2 publication Critical patent/WO1997035194A2/fr
Publication of WO1997035194A3 publication Critical patent/WO1997035194A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Definitions

  • ligands regulates almost all biological processes, such as immune recognition, cell signaling and communication, transcription and translation, intracellular signaling, and catalysis, .i.e., enzyme reactions.
  • ligands such as hormones, growth factors, and neurotransmitters; which induce B-cell (antibody-mediated) or T-cell (cell-mediated) immunity; which can catalyze chemical reactions; or which can regulate gene expression at the level of transcription or translation.
  • combinatorial libraries are collections of differing molecules which can be prepared either synthetically or biosynthetically and screened for biological activity in a variety of formats.
  • combinatorial libraries can be synthesized by batch processes and, importantly, the molecular identity of individual members of the library can be ascertained in a drug screening format.
  • a variety of combinatorial approaches have been described in the art.
  • the most widely used techniques for screening large peptide libraries typically comprises cloning the peptide-encoding gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.
  • Such illustrative assays are amenable to high through-put analysis which is necessary to screen large numbers of potential peptide agonists or antagonists.
  • the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind a target molecule, such as a receptor protein via this gene product is detected in a "panning assay".
  • the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) Bio/Technology 9: 1370-1371; and Goward et al. (1992) ⁇ BS 18:136-140).
  • the peptide library is expressed as fusion proteins on the surface of a viral particle.
  • foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits.
  • coli filamentous phages M13, fd., and fl are most often used in phage display libraries, as either of the phage gUI or gNUl coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J 12:725-734; Clackson et al. (1991) Nature 352:624-628; and Barbas et al.
  • molecules with "natural" stereochemistries are often less preferable than their "unnatural" enantiomers (L-D ⁇ A, L-R ⁇ A, D-peptides) because natural enantiomers can be limited in use by poor pharmacokinetic profiles due to in vivo processing.
  • L- peptides can be rapidly degraded by proteases after administration to an animal, thus requiring a higher effective dose.
  • pharmaceutical peptides can elicit strong immunogenic responses in patients, further contributing to their rapid clearance.
  • Non-hydrolyzable peptide analogs such as retro-inverso analogs (cf, Sisto et al. U.S. Patent 4,522,752), retro-enantio analogs (c , Goissis et al. (1976) J Med Chem 19:1287-90); trans-olefin derivatives (c , Shue et al. (1987) Tetrahedron Letters 28:3225); and phosphonate derivatives (c , Loots et al., in Peptides: Chemistry and Biology, (Escom Science Publishers, Leiden, 1988, p. 118).
  • retro-inverso analogs cf, Sisto et al. U.S. Patent 4,522,752
  • retro-enantio analogs c , Goissis et al. (1976) J Med Chem 19:1287-90
  • trans-olefin derivatives c , Shue et al. (1987) Te
  • the backbone of the peptide is altered in order to render the peptidomimetic resistant to proteolysis.
  • the resulting peptidomimetic can suffer from decreased bioactivity through loss of certain binding contacts between the natural peptide backbone and target receptor, as well as changes in the steric space relative to the peptide due to alteration in dihedral angles and the like.
  • D-DNA and D-RNA can be rapidly degraded by nucleases after administration to an animal, thus requiring a high effective dose.
  • D-peptides and L-DNA and L-RNA have increased resistance to peptidases and nucleases, respectively (Zawadzke and Berg (1992) J Am Chem Soc 114:4002; Holy and Sorm (1969) Collect Czech Chem Commun 34:3383; Tazawa et al. (1970) Biochemistry 9:34-99; Ashley (1992) J Am Chem Soc 114:9732).
  • the present invention makes available a powerful directed approach for identifying enantioselective compounds which bind to biological targets.
  • the present invention relates, in one aspect, to a method for identifying compounds which interact with a target molecule, by (i) contacting a screening molecule with a variegated compound library, wherein the screening molecule comprises solid target molecule, or the enantiomer thereof if the target molecule is chiral; (ii) selecting, from the library, compounds which have a desired interaction with the target molecule; and (iii) testing the ability of the enantiomer of a compound selected in step (/ ' /) to interact with the target molecule.
  • the target molecule is chiral, and the screening molecule comprises the enantiomer of the target molecule.
  • target molecules include an polypeptides, nucleic acids, carbohydrates and other chiral polymers, as well as steroisomers of non-polymeric molecules, such as steroids, inositols, lipid soluble vitamins, terpenes, acetogenims, chiral neurotransmitters, or a transition state analog.
  • the target molecule is achiral.
  • variegated compound library such as peptide libraries, nucleic acid libraries and carbohydrate libraries.
  • Other variegated compound libraries contemplated by the present invention include small organic molecule libraries, and a natural product extract libraries, such as isolated from animals, plants, fungus and/or microbes.
  • the method is directed to identifying ligands for a target protein.
  • the method can be carried out according to the steps of (i) combining a D-enantiomer of a target protein (a D-target protein), and a variegated compound library; (ii) selecting one or more compounds from the library which have a desired binding interaction with the D-target protein; and (iii) testing the ability of the enantiomer of a compound selected in step (ii) to interact with the target protein.
  • a variety of variegated compound libraries can be used.
  • the variegated compound library is a peptide library.
  • libraries can be provided as peptide phage display libraries, or as bacterial cell-surface display or spore display libraries.
  • the library is a collection of synthetic peptides, and may, for example, be present free in solution or linked to an insoluble support.
  • each peptide of the peptide library is associated with an index providing the molecular identity of the peptide associated therewith.
  • the protein target can be, to illustrate, a receptor, an enzyme, a DNA-binding protein or a protein complex, or a portion thereof which retains a screenable activity.
  • screening targets which correspond to (e.g. include) such domain structures as: SH2 domains; SH3 domains; ankyrin-like repeats; WD40 motifs; Kunitz-type inhibitor domains; growth factor-like domains such as EGF-like domains; Kringle domains; fibronectin finger-like domains; heparin-binding domains;; death domains; TRAF domains; pleckstrin homology (PH) domains; ITAMs; catalytic domains such as kinase domains; phosphatase domains; phospholipase domains; guanine nucleotide exchange factor (GEF) domains; and hydrolase domains (such as protease domains); or DNA binding domains such as leucine zippers, zinc fingers and helix-
  • the D-target protein is soluble. In other preferred embodiments, the D-target protein has a molecular weight of less than 50kd, more preferably less than 40kd, and even more preferably less than 25kd. Preferred D-target proteins include less than 500 amino acid residues, more preferably less than 250 amino acid residues, and even more preferably less than 200 amino acid residues. In still other embodiments, the D-target protein is provided in a lipid bilayer with at least a portion of the D-target protein accessible to an aqueous phase for interaction with the compound library.
  • the peptides are selected from the peptide library by a differential binding means comprising affinity separation of peptides which specifically bind the D-target protein from peptides which do not specifically bind.
  • the differential binding means can include panning the peptide library with a D-target protein immobilized on an insoluble surface.
  • the peptides are selected from the display library based on an ability to modulate protein-protein or protein-DNA binding by the target protein, or based on an ability to modulate an enzymatic activity of the target protein.
  • D-enantiomer peptide ligands can be identified for a target protein, by: (a) transforming suitable host cells with a library of replicable phage vectors encoding a library of phage particles displaying a fusion coat protein, the fusion coat protein comprising a phage coat protein portion and a test peptide portion, the test peptide portion being encoded by a variegated gene library; (b) culturing the transformed host cells such that the phage particles are formed and the fusion coat proteins are expressed; and (c) selecting any of the phage particles having a peptide portion which binds to a D-enantiomer of a selected target protein.
  • the D-enantiomer corresponding to the peptide portion are ligands for the L-enantiomer of the target protein, and the molecular identity of the peptide portion is provided by the phage vector.
  • the phage particles can be selected by a differential binding means comprising contacting the phage particles with the D-target protein and separating phage particles which specifically bind the D-target protein from phage particles which do not specifically bind the D-target protein.
  • the differential binding means can include an affinity chromatographic means in which the D-target protein is provided as a component of an insoluble matrix, such as a polymeric support.
  • the differential binding means comprises precipitating the phage particles with a multivalent form of the D-target protein, and subsequently removing non-specifically bound phage particles from the precipitate.
  • Preferred phage particles are selected from a group consisting of Ml 3, fl, fd, Ifl, Ike, Xf, Pfl, PD, ⁇ ,T4, T7, P2, P4, ⁇ X-174, MS2 and f2.
  • filamentous bacteriophage specific for Escherichia coli such as the filamentous bacteriophage is selected from a group consisting of Ml 3, fd, and fl .
  • kits for identifying D-enantiomer peptide ligands for a target protein comprising (i) a D-enantiomer of a target protein (a
  • the variegated population of test peptides includes at least 10 3 different peptide sequences, though more preferably at least IO 6 , IO 7 , or IO 8 .
  • at least one of the D-target protein and the variegated population of test peptides includes a detectable label.
  • the D-target protein has a molecular weight less than 25,000 daltons, more preferably less than 20kd, 15kd and, in some embodiments, lOkd.
  • the test peptides are from 2-25 amino acid residues in length, and may be provided as part of a phage display library or as a collection of synthetic peptides.
  • Yet another aspect of the invention relates to compounds, such D-enantiomers of peptides identified by the subject method, and their uses.
  • Figure 1 is a schematic overview of a method for identifying enantiomer ligands for a biological target.
  • A has the same affinity for D as B has for C.
  • Figures 2 A and 2B illustrate degenerate gene sequences for 15-mer and 6-mer peptide libraries, respectively.
  • Figure 3 shows different 6-mer sequences selected in an assay using D-IL-8.
  • Figure 4 shows different 15-mer sequences selected in an assay using D-LL-8.
  • Figure 5 shows two exemplary consensus sequences after panning with D-IL-8.
  • Figures 6 and 7 show selected peptide sequences obtained by panning, while Figure 8 shows the consensus sequences which are evident from the isolated peptides.
  • the present invention makes available a powerful directed approach for identifying enantioselective compounds which bind to biological targets.
  • the invention is depicted in a preferred form in Figure 1.
  • the chiral target (A) may be any chiral molecule that could potentially be synthesized or purified in its enantiomeric (mirror image) form (B).
  • Target A may be a known molecule, or it may be a fragment or derivative of a known molecule. It may be large (e.g. DNA, RNA, protein, carbohydrate, lipid or combinations and/or modifications thereof) or it may be small (e.g. metabolites, hormones, transition state analogs, and drugs).
  • Examples of large molecules that have been prepared as enantiomers are DNA, RNA, and protein (Garbesi et al. (1993) Nucl Acids Res 21:4159; Visser et al. (1986) Reel Trav Chim Pays Bas 105:528; Zawadzke and Berg supra).
  • Examples of small molecules that have been prepared as enantiomers are glucose, norepinephrine and cocaine (Lehringer (1975) Biochemistry (Worth Publishers, NY):252; Iversen et al. (1971) Br J Pharmac 43:845; Lewin et al. (1987) J Heterocyclic Chem 24:19.).
  • the library of chiral molecules can be a natural product library, a library of known compounds, or a combinatorial library. Libraries that are biologically amplifiable are particularly important because these are the most diverse libraries that can be screened (currently as many as 10 13 molecules can be concurrently screened [Bartel and Szostak (1993) Science 261 : 1411]), and biologically amplifiable libraries cannot be created in enantiomeric form because biological amplification requires "natural" enantiomers.
  • a related strategy to that of Figure 1 is also envisioned for achiral targets.
  • target structures A and B of Figure 1 would be identical.
  • Achiral target (B) in Figure 1 would be screened with a chiral library to yield a high affinity chiral ligand (C).
  • Either this ligand C or its enantiomer D could be used as ligand for the achiral target B.
  • Ligand D may have preferable pharmacokinetic properties to ligand C (see above). Examples of such achiral targets would be dopamine and serotonin (Adrich Catalog (1994-95) p. 812; p. 1248).
  • the subject method is directed to the generation of D-peptide enantiomers.
  • the subject method permits the selection and amplification of D-peptide ligands, the mirror images (enantiomers) of natural L-peptides by a process which first exploits advantages to library generation with L-amino acids.
  • the subject method generally comprises the steps of generating a variegated library of test compounds, and selecting from the library those compounds which have a desired interaction with a target protein.
  • the peptide library can be provided with L-amino acids, while the target protein is generated from D-enantiomers of amino acids so as to provide a mirror image of the naturally occurring target protein (e.g., the L-enantiomer).
  • the peptides of the library can be presented by a display package, free in solution, or immobilized on an insoluble support, and screened for binding to the enantiomeric D-protein target.
  • affinity selection techniques and the like can be utilized to isolate from the population of test peptides those peptides which have a desired binding specificity for the D-target protein enantiomer.
  • the D-enantiomer of the L-peptide ligand is synthesized ( Figure 1) for use as a specific ligand of the original chiral L-protein target.
  • this D-peptide ligand will have the same affinity for the L-protein target as the L-peptide ligand of the library had for the D-protein target.
  • This D-peptide can then be evaluated for inherent biological activity or other utility.
  • the subject method by providing a privileged platform, provides access to three dimensional shape space in a manner which was not readily available by prior art methods. Because both the peptide library and protein target display side chains in a unique, specific directional sense, the present method is a structurally selective approach in addition to scoring for interaction of functional groups.
  • the subject method overcomes certain of the weaknesses of drug design described above, and provides a powerful selection and amplification method that allows the production of ligands with the same diversity as peptides, but with the greatly improved pharmacokinetic profiles needed for drug activity.
  • D-peptides are very resistant to degradation by proteases and mammahan serum (Wade et al. (1990) PNAS 87:4761) because of the specificity of biological enzymes for natural enantiomers.
  • D-peptides and D-proteins do not elicit strong immune responses (Dintzis et al. (1993) Proteins Struct. Fund. Genet. 16:306).
  • D-peptides are resistant to degradation by proteases into the smaller fragments necessary for presentation by major histocompatibility complex (MHC) class I and II proteins;
  • MHC major histocompatibility complex
  • D-peptides may not bind productively to the L-peptide-binding groove of MHC class I and ⁇ molecules because the groove is chiral and therefore probably specific for L- peptides (Parham P (1992) Nature 360:300); and
  • D-peptides do not have the repetitive features found in strongly immunogenic non-protein antigens, such as carbohydrates.
  • the synthesis of an L-peptide library rather than a D-peptide library can be economically more feasible.
  • the present method can be used to identify new leads, as well as refine existing pharmacophoric peptides.
  • the D-enantiomer ligands accessible by the subject method include agonists (e.g., mimetics) of existing ligands, as well as antagonists, and the protein targets include receptors, enzymes, DNA binding proteins, signal transduction proteins, etc.
  • Amino acid residues in peptides are abbreviated as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is lie or I; Methionine is Met or M; Valine is Val or V; Serine is Ser or S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gin or Q; Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Arg or R; and Glycine is Gly or G.
  • ligand refers to a molecule that is recognized by a particular protein, e.g., a receptor. Any agent bound by or reacting with a protein is called a "ligand,” so the term encompasses the substrate of an enzyme and the reactants of a catalyzed reaction.
  • ligand does not imply any particular molecular size or other structural or compositional feature other than that the substance in question is capable of binding or otherwise interacting with a protein.
  • a "ligand” may serve either as the natural ligand to which the protein binds or as a functional analogue that may act as an agonist or antagonist.
  • substrate refers to a substrate of an enzyme which is catalytically acted on and chemically converted by the enzyme to product(s).
  • receptor refers to a molecule that has an affinity for a given ligand.
  • Receptors may be naturally-occurring or synthetic molecules.
  • the D-amino acid enantiomer of a receptor can be employed in the present invention in its isolated state or as an aggregate with other species or in some modified form.
  • the term "peptide” refers to an oligomer in which the monomers are amino acids (usually alpha-amino acids) joined together through amide bonds. Peptides are two or more amino acid monomers long, but more often are between 5 to 10 amino acid monomers long and can be even longer, i.e.
  • polypeptides up to 20 amino acids or more, although peptides longer than 20 amino acids are more likely to be called "polypeptides.”
  • protein is well known in the art and usually refers to a very large polypeptide, or set of associated homologous or heterologous polypeptides, that has some biological function.
  • peptide polypeptide
  • protein protein
  • random peptide library refers to a set of random or semi-random peptides, as well as sets of fusion proteins containing those random peptides (as applicable).
  • carbohydrate embraces a wide variety of chemical compounds having compositions similar to the general formula (CH 2 O)-., such as monosaccharides, disaccharides, oligosaccharides. and polysaccharides. Oligosaccharides are chains composed of saccharide units, which are alternatively known as sugars. These saccharide units can be arranged in any order and the linkage between two saccharide units can occur in any of approximately ten different ways. As a result, there are a number of different possible stereoisomeric oligosaccharide chains of the same or similar molecular formula.
  • reporter group refers to an atom, compound, or biological molecule or complex that can be readily detected when attached to other molecules and exploited in chemical separation processes.
  • a reporter group can be, for example, a fluorescent or radioactive atom or a compound containing one or more such atoms.
  • solid support refers to a material having a rigid or semi-rigid surface. Such materials will preferably take the form of small beads, pellets, disks, chips, dishes, multi-well plates, wafers or the like, although other forms may be used. In some embodiments, at least one surface of the substrate will be substantially flat.
  • surface refers to any generally two-dimensional structure on a solid substrate and may have steps, ridges, kinks, terraces, and the like without ceasing to be a surface.
  • the language “display package” describes a biological or chemical particle (such as a bead or the like) which has one or more peptides provided on its surface in order that such peptides may interact, if at all, with a target protein.
  • the display package further includes encoded information providing the particle with the identity of the associated peptide.
  • a variegated mixture of display packages encoding at least a portion of the test peptide library is also referred to as an "peptide display library”.
  • the language "replicable genetic display package” describes a biological display package which has genetic information providing the package with the ability to replicate.
  • the package can display a fusion protein including peptide derived from the variegated peptide library.
  • the test peptide portion of the fusion protein is presented by the display package in an context which permits the peptide to bind to a target protein that is contacted with the display package.
  • the display package will generally be derived from a system that allows the sampling of very large variegated peptide libraries, as well as easy isolation of the recombinant genes from purified display packages.
  • the display package can be, for example, derived from vegetative bacterial cells, bacterial spores, and bacterial viruses (especially DNA viruses).
  • differential binding means refer to the separation of members of the peptide display library based on the differing abilities of test peptides on each of the display packages of the library to bind to the target protein.
  • the differential binding of a target protein by peptides of the display can be used in the affinity separation of peptides which specifically interact with the target protein from peptides which do not.
  • affinity selection means include affinity chromatography, precipitation, fluorescence activated cell sorting, and plaque lifts. As described below, the affinity chromatography includes panning techniques using, e.g. immobilized target proteins.
  • fusion protein and "chimeric protein” are art-recognized terms which are used interchangeably herein, and include contiguous polypeptides comprising a first polypeptide covalently linked via an amide bond to one or more amino acid sequences which define polypeptide domains that are foreign to and not substantially homologous with any domain of the first polypeptide.
  • One polypeptide from which the fusion protein is constructed comprises a recombinant test peptide derived from a variegated gene library.
  • a second polypeptide portion of the fusion protein is typically derived from an outer surface protein or display anchor protein which directs the "display package" (as hereafter defined) to associate the test peptide with its outer surface.
  • this anchor protein can be derived from a surface protein native to the genetic package, such as a viral coat protein.
  • the fusion protein comprises a viral coat protein and a test peptide it will be referred to as an "peptide fusion coat protein".
  • the fusion protein may further comprise a signal sequence, which is a short length of amino acid sequence at the amino terminal end of the fusion protein, that directs at least a portion of the fusion protein to be secreted from the cytosol of a cell and localized on the extracellular side of the cell membrane.
  • vector refers to a DNA molecule, capable of replication in a host cell, into which a gene can be inserted to construct a recombinant DNA molecule.
  • phage vector and “phagemid” are art-recognized and generally refer to a vector derived by modification of a phage genome, containing an origin of replication for a bacteriophage, and preferably, though optional, and origin for a bacterial plasmid.
  • the use of phage vectors rather than the phage genome itself provides greater flexibility to vary the ratio of chimeric test peptide/coat protein to wild ⁇ type coat protein.
  • helper phage describes a phage which is used to infect cells containing a defective phage genome or phage vector and which functions to complement the defect.
  • the defect can be one which results from removal or inactivation of phage genomic sequence required for production of phage particles.
  • helper phage examples include M13K07, and M13K07 gene HI no. 3.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • a “D-enantiomer” or “D-peptide enantiomer” refers to a peptide comprised of D-amino acid residues, as opposed to L-amino acids.
  • the terms "D-amino acid” and “L-amino acid” each denote an absolute configuration by convention relative to the possible stereoisomers of glyceraldehyde. Thus, all stereoisomers that are stereochemically related to L-glyceraldehyde are designated L-, and those related to D-glyceraldehyde are designated D-, regardless of the direction of the rotation of plane of polarized light by the given isomer.
  • threonine and isoleucine there are two stereochemical centers, i.e., the C ⁇ and the C ⁇ atoms.
  • the D-threonine and D-isoleucine employed herein preferably have stereochemistries at both chiral sites which are opposite (enantiomeric) to the stereochemistry of the L-enantiomers of those amino acids, e.g., they are complete mirror images.
  • Glycine is the only commonly occurring achiral amino acid. Accordingly, when a peptide is designated herein as a D- or L- enantiomer, it is meant that essentially all of the chiral amino acid residues comprising such peptide have the indicated chirality. The presence of achiral amino acid residues such as glycine do not affect the designation of its chirality. All chiral amino acids in protein described in nature, e.g., "naturally occurring" are L-amino acids.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • enantiomers refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
  • Diastereomers refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another. With respect to the nomenclature of a chiral center, terms “D” and “L” configuration are as defined by the IUPAC Recommendations. As to the use of the terms, diastereomer, racemate and enantiomer will be used in their normal context to describe the stereochemistry of peptide preparations.
  • enantiomerically enriched refers to preparations of a chiral compound which substantially lacks one of the enantiomers.
  • enantiomerically enriched refers to a preparation in which the D-enantiomer sidechains are enriched, compared to a control mixture of the protein made with naturally occurring amino acid precursors, e.g., L- amino acids. Unless otherwise specified, such terms refer to peptide compositions in which the ratio (D) and (L) enantiomers is greater that 1:1 by weight.
  • an enantiomerically-enriched preparation of a D-target protein means a preparation having greater than 50% by weight of the peptide derived from D-amino acid enantiomers relative to the L-enantiomers, more preferably at least 75% by weight, and even more preferably at least 85% by weight.
  • the enrichment can be much greater than 85%, providing a "substantially enantiomerically enriched" or “substantially non- racemic" preparation, which refers to preparations of a peptide which have greater than 90% of the D-enantiomer relative to the L-enantiomer, and even more preferably greater than 95%.
  • the term "substantially free of the L-enantiomer” will be understood to have similar purity ranges.
  • (D)-enantiomeric targets are substantially free of (L)- protein.
  • substantially free as used herein, means the same ranges as “substantially enantiomerically enriched” above.
  • the screening target can be, in one embodiment, any chiral molecule of biological significance.
  • the target can be a polymer of repeating chiral subunits, such as a polypeptide, a nucleic acid, a carbohydrate, or cell wall components.
  • the target may alternatively be a non-polymeric molecule containing one or more chiral centers, such as a steroid, opioid, macrolid, or other macrocyclic compound.
  • enzymes to produce optically enriched products is also increasing (e.g., M.P. Scheider, ed. "Enzymes as Catalysts in Organic Synthesis", D. Reidel, Dordrecht (1986).
  • enantiomers can be accomplished in several ways known in the art. For example, a racemic mixture of two enantiomers can be separated by chromatography, using a chiral stationary phase (see, e.g., "Chiral Liquid Chromatography", W.J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers.
  • the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like.
  • diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid.
  • the target molecule can be an achiral molecule.
  • the enantiomers of chiral ligands identified to such achiral targets may have preferable pharmacokinetic properties to the initially identified ligand C. If a chiral ligand already exists for an achiral target, an enantiomeric ligand can be prepared without having to perform the screening step.
  • the screening target is a polypeptide derived from D-amino acids.
  • the D-polypeptide target can range in size from a short peptide, e.g. dipeptide, to a full length protein.
  • a D-polypeptide target can be prepared by any means available to one skilled in the art.
  • the precise method employed for synthesizing the polypeptide is not considered essential to the subject method, and is therefore not to be considered as limiting, particularly as technology develops new ways to synthesize and assemble polypeptides de novo.
  • SPPS stepwise solid phase peptide synthesis
  • D-amino acids suitable for polypeptide synthesis are commercially available from, for example, Peptide Institute (Osaka, Japan), Peptides International (Louisville, KY), Bachem Bioscience (Philadelphia, PA), and Bachem California (Torrance, CA).
  • Appropriate protective groups usable in such synthesis are described in the above-referenced texts, as well as by McOmie in Protective Groups in Organic Chemistry. Plenum Press, New York, 1973.
  • SPPS has been used to synthesize a variety of proteins possessing biological activity, including ribonuclease A (Hirschmann et al. (1969) J Am Chem Soc 91:502; Gutte and Merrifield (1971) JBiol Chem 246:1922), the C-terminal domain of the HTV- 1 gag p24 protein (Mascagni et al. (1990) Tetrahedron Lett 31:4637-4640), interleukin- 3 (Clark-Lewis et al. (1986) Science 231:134-139), insulin-like growth factor (Li et al. (1985) PNAS 80:2216-2220), epidermal growth factor (Heath et al. (1986) PNAS 83:6367-6371), interleukin-8 (Clark-Lewis (1991) Biochemistry 50:3128-3134), fflV-1 '7
  • An alternative to the stepwise construction of long peptide chains is to individually synthesize segments of the target protein and then chemically couple the segments to form the full length protein.
  • This convergent synthesis procedure has the obvious advantage that the smaller fragments (e.g., ⁇ 100 amino acids) are easier to synthesize and purify.
  • the side chain functionalities of the peptide fragments are protected and the peptide fragments joined using the same chemistry to create a peptide bond between the two fragments.
  • more preferred techniques have been developed for the total chemical synthesis of proteins.
  • Chemical ligation is not limited to formation of a peptide bind at the ligation site.
  • a variety of ligation chemistries can be used to implement the strategy.
  • Exemplary chemoselective ligation reactions include thioester-forming ligations (Schnolzer et al., supra) and oxime-forming ligations (Rose (1994) J Am Chem Soc 116:30-34).
  • Other chemistries of potential utility in the formation of a D-amino acid target protein by chemoselective ligation include hydrozone formation (Gaertner et al.
  • a preferred linkage is a thiol ester linkage.
  • This linkage can be accomplished by first attaching a facile leaving group to a first peptide segment and by attaching a carbonylthiol functionality to a second peptide segment.
  • the two segments are covalently joined by nucleophilic substitution involving the sulphur nucleophile attacking the leaving group. For example, as illustrated below, a sulfur nucleophile at the terminus of one peptide segment is used to attack an alkyl bromide at the terminus of the other segment.
  • the two halves of the target protein are chemically synthesized by SPPS method using D-amino acid precursors, the peptides cleaved, deprotected with hydrogen fluoride, and purified by high performance liquid chromatography (Schn ⁇ lzer et al., supra).
  • the amino terminus of that fragment is functionalized with bromoacetic anhydride.
  • 4-[ ⁇ -(Boc-Gly-S)benzyl]phenoxyacetamidomethyl- resin is used as the resin support which releases the carbonylthiol.
  • the ligation reaction is carried out by mixing the amino- and carboxyl-terminal halves under normal ligation reaction conditions optimized for peptide solubility (e.g., 6 M guanidine hydrochloride, 0.1 M sodium phosphate buffer at pH 4.3).
  • normal ligation reaction conditions optimized for peptide solubility (e.g., 6 M guanidine hydrochloride, 0.1 M sodium phosphate buffer at pH 4.3).
  • the use of two or more mutually exclusive ligation chemistries can be used to ligate three or more peptide segments in a specific manner.
  • the thioester- and oxime-forming chemistries can be used in a modular approach to the synthesis of a protein through several peptide fragments.
  • the synthesis of functional analogs by such methods have permitted the synthesis of large proteins, and is particularly amenable to the synthesis of protein which possess numerous discrete domains, as for example many of the proteins in involved in clot formation and dissolution fibrinolysis.
  • TASP template-assembled synthetic protein
  • TASP template-associated synthetic protein
  • component amphiphilic peptides particularly those preferring ⁇ -helical and ⁇ -sheet structures, are assembled by covalent bonds to a carrier or template molecule which is said to direct "the peptide chains into protein-like packing arrangements.”
  • the resultant molecule has a branched structure in which a number of peptides extend from the template. Oligopeptides, in particular, are employed as template molecules.
  • the TASP molecules are synthesized by a chemoselective ligation approach.
  • a readily prepared synthetic helical peptide- ⁇ COSH see above
  • a synthetic (BrAc) n template molecule can be used to generate multi-helical assemblies (see, for example, Dawson et al. (1993) J Am Chem Soc 115:7263-7266).
  • Another approach, suitable for the preparation of multimeric proteins e.g. MUC-1, which contains a multimer of a 20-amino-acid sequence, is to first synthesize the monomeric peptide (e.g.
  • the target should be associated with a biological significant process, such as a disease process.
  • Extracellular targets are preferred because these are most accessible to hydrophylic D-peptides.
  • intracellular targets may also be considered because they are accessible to peptides that (a) directly cross the membrane due to their intrinsic hydrophobicity, (b) cross the membrane via endocytosis or prinocytosis, or (c) are delivered across the membrane by transposing agents such as liposomes.
  • Transmembrane targets are also suitable because potential solubility problems may be overcome when they are synthesized in fragments (see the example of the IL-8 receptor below).
  • the target fragment does not contain modifications, such as glycosylations, that are necessary for activity because these are more difficult to synthesize.
  • modifications such as glycosylations
  • polypeptide screening target factors which can be considered include solubility, peptide chain length, requirement of post-translational modifications, or addition of co-factors, and/or monomeric or oligomeric nature of protein(s) upon which the target is based.
  • the polypeptide target it will be desirable that the polypeptide target be soluble.
  • Many of the cytosilic and extracellular proteins which are contemplated as candidates for development of D-polypeptide targets can be chemically synthesized in their full-length form as soluble molecules.
  • the screening polypeptide can be derived from a smaller portion of the protein of interest.
  • the target can be generated as the D-enantiomer of a domain, or other portion of the protein, which retains a biological activity against which a compound library is to be screened.
  • domains and/or motifs are well known that, even when isolated from the full-length protein, retain such activities as ligand binding or catalytic activity. Accordingly, the present invention contemplates screening targets which correspond to (e.g.
  • domain structures include) such domain structures as: SH2 domains; SH3 domains; ankyrin-like repeats; WD40 motifs; Kunitz-type inhibitor domains; growth factor-like domains such as EGF-like domains; Kringle domains; fibronectin finger-like domains; heparin-binding domains;; death domains; TRAF domains; pleckstrin homology (PH) domains; ITAMs; catalytic domains such as kinase domains; phosphatase domains; phospholipase domains; guanine nucleotide exchange factor (GEF) domains; and hydrolase domains (such as protease domains); or DNA binding domains such as leucine zippers, zinc fingers and helix-loop-helix motifs.
  • domain structures as: SH2 domains; SH3 domains; ankyrin-like repeats; WD40 motifs; Kunitz-type inhibitor domains; growth factor-like domains such as EGF-like
  • the screening target can be derived from a soluble extracellular or cytoplasmic domain.
  • the screening target can be the D-enantiomer of a soluble ligand binding domain of a cell surface receptor.
  • the screening target can correspond to the extracellular domain of a guanylyl cyclase, a cytokine receptor, a tyrosine kinase receptor, or a serine/thermine kinase receptor.
  • the screening target can correspond to a soluble portion of a G-protein coupled receptor (GCR) which retains ligand binding activity.
  • GCR G-protein coupled receptor
  • the screening target can be reconstituted in a lipid bilayer, such as a liposome or other vesicle (see, for example, Kalva Kolanu et al. (1990) Biotechniques 11:248; and The Huang U.S. Patents 4,957,735 and 4,708,933) and the lipid protein combination used as the screening target.
  • the selection of amino acid length is, on the one hand, related to the solubility issue, and on the other hand, related to the issue of chemical synthesis.
  • screening targets are in the range of 50-500 amino acids in length, preferably less than 400 residues, and even more preferably less than 200.
  • the screening target can be a short peptide sequence, e.g. less than 50 residues, including peptides as small as dipeptides.
  • modification of the screening target is desired to correspond to the post ⁇ translational modification of the natural protein
  • standard chemical coupling with non- peptide and peptide functionalities can be provided.
  • the target can be glycosylated, prenylated, phosphorylated, etc. to resemble actual post-translational modification.
  • the added moiety is itself chiral, the opposite enantiomer of that naturally occurring with the protein can be provided with the screening target.
  • the target protein is the gastrin-releasing peptide (GRP).
  • GRP gastrin-releasing peptide
  • SCLC small-cell lung cancer
  • An excellent therapeutic target for SCLC is gastrin-releasing peptide, a 27-amino-acid-long bombesin-like growth factor (Marx et al. (1984) PNAS 81:5699; and Cuttitta et al. (1985) Nature 316:823).
  • Human SCLC cell lines secrete GRP which, in turn, can stimulate the growth of these cell lines in vitro (Cuttitta et al., supra).
  • the subject method can accordingly be derived to develop D-amino acid peptides which, by interfering with the binding of GRP to its cognate receptor, may be used as anti-proliferative agents to inhibit GRP-stimulated cell growth.
  • Another potential therapeutic target are receptors from the neu receptor family.
  • breast cancer is the most common cancer and is only second to lung cancer in the number of cancer deaths.
  • a prime breast cancer target is neu/erbB- 2 HER-2, a 185 kD trans-membrane phosphoglycoprotein tyrosine kinase (Shih et al. (1981) Nature 290:261).
  • Amplification or over expression of the neu oncogene occurs in about 30% of breast and ovarian adenocarcinomas, a finding that correlates with a poor response to primary therapy (Slamon et al. (1987) Science 235:177; and Hayes et al.
  • MAbs and their radiolabelled conjugates that bind to the extracellular domain of neu retard the growth of breast cancer cells in culture and in nude mice without the selection of neu-negative cell clones (DeSantes et al. (1992) Cancer Res. 52:1916; and Drebin et al. (1986) PNAS 83:9129.).
  • Such MAb conjugates which are now in clinical trials (Lippman et al. (1993) Science 259:631), may alter the neu signal transduction pathway and affect tumor growth in several different ways. They may (i) over stimulate neu, thereby causing differentiation (Bacus et al. (1992) Cancer Res.
  • the neu receptor shares 39-50% identity with the extracellular domain of the epidermal growth factor receptor (EGFR) that contains a 202-amino-acid-fragment sufficient for high affinity binding to epidermal growth factor and transforming growth factor alpha (Kohda et al. (1993) J. Biol. Chem. 268: 1976). Furthermore, an eight- amino-acid fragment of neu (termed neuRL2) from the putative ligand-binding domain inhibits the phosphorylation of neu and the growth of breast cancer cells in a dose- dependent manner, but does not inhibit cells lacking neu. It was concluded that the neuRL2 peptide probably bound to, and inactivated, a neu ligand (Neri et al. First SPORE Investigator's Meeting, Rockville, Maryland. Abstract #2, July 18-20, 1993 (submitted for publication in May, 1995)). Thus, this eight-amino-acid fragment of neu is a good target for anti-neu drug design.
  • EGFR epidermal growth factor receptor
  • the D-peptides which can be derived by the present invention can be useful inhibiting the biological function of neu by, for example, competitively disrupting the binding of neu with its ligand or other protein, or preventing allosteric activation of an enzymatic activity associated with neu. Alternatively, they may be useful as agonists causing over stimulation or down-regulation of neu.
  • Interleukin-8 is a chemoattractant and activator of neutrophils, and has been implicated in a wide range of acute and chronic inflammatory diseases (Murphy (1994) Annu. Rev. Immunol. 12:593-633).
  • Human LL-8 is a 72-amino-acid-long polypeptide produced by monocytes, fibroblasts, keratinocytes and endothelial cells upon induction by factors such as tumor necrosis factor, interleukin- 1, and lipopolysaccharides (Murphy, supra).
  • IL-8 act as LL-8 antagonists in vitro by inhibiting neutrophil activation (chemotaxis, exocytosis and respiratory burst), suggesting that anti-IL-8 agents may have therapeutic potential for inflammatory diseases (Moser et al. (1993) J. Biol. Chem. 268: 7125- 7128).
  • the monomeric JL-8 peptide forms dimers in vitro with a Kd of 20 ⁇ M (Paolini et al. (1994) J Immunology 153: 2704; and Burrows et al. (1994) Biochemistry 33:12741-12745), so it is possible that the monomer and/or the dimer are active in vivo.
  • an alternative target from IL-8 is a functional fragment of the JL-8 receptor. Fragments of the human and rabbit IL-8 Type 1 receptor of 39 and 44 amino acids, respectively, are functional in IL-8 binding assays (Gayle et al. (1993) JBiol Chem 268:7283-7289). Thus, members of the largest receptor family, the seven transmembrane receptors, are potential targets, because these fragments could be readily synthesized as D-peptides for use as targets.
  • Small ligand-binding fragments of other receptors have also been determined using an ingenuous method. For example, small regions of the human thyrotropin receptor capable of hormone binding were determined by synthesizing overlapping peptides of the proposed hormone-binding domain and assaying them for binding activity. (Atassi et al. (1991) PNAS 88:3613-3617). Such an approach could be applied to any receptor.
  • the cellular proto-oncogene c-myc is involved in cell proliferation and transformation but is also implicated in the induction of programmed cell death (apoptosis).
  • the c-Myc protein is a transcriptional activator with a carboxyl-terminal basic region/helix-loop-helix (HLH)/leucine zipper (LZ) domain. It forms heterodimers with the HLH/LZ protein Max and transactivates gene expression after binding DNA E- box elements.
  • the protein Max is the obligatory partner of c-Myc for many its biological functions analyzed to date. For instance, Myc must heterodimerize with Max to bind DNA and perform its oncogenic activity.
  • the subject method can be used to derive D- amino acid peptides which can inhibit formation of complexes between Myc and other proteins such as Max, and/or which can inhibit the binding of a Myc complex to a myc- A >
  • fibronectin a glycoprotein involved in cell adhesion, tissue organization and wound healing.
  • the total synthesis of fibronectin modules is described by, for example, Williams et al. (1994) JAm Chem Soc 116:10797-10798.
  • HTV-l human immunodeficiency virus type 1 major gag protein
  • p24 human immunodeficiency virus type 1 major gag protein
  • the total synthesis of a C- terminal 100 amino acid fragment of p24 is described by Mascagni et al. (1990) Tetrahedron Lett 31 :4637-4640, and that portion of the p24 protein, as a D-enantiomer, can be used to generate a screening target
  • TGF ⁇ total synthesis of TGF ⁇ has been described by Woo et al. (1989) Protein Eng 3:29-37, and accordingly provides a possible target molecule.
  • HIN protease has been synthesized by total chemical synthetic means (Kent et al. PCT Publication WO93/20098) and provides a unique target for developing inhibitors of the catalytic activity as well as inhibitors of protein-protein interactions involving the protease.
  • the screening target can be an L-nucleic acid such as single or double-stranded L-D ⁇ A or single or double-stranded L-R ⁇ A, where the natural D-ribose is replaced by its enantiomer L-ribose.
  • L-D ⁇ A and L- R ⁇ A The synthesis of L-D ⁇ A and L- R ⁇ A is described in the art. See, for example, Visser et al (1986) Reel Trav Chim Pays Bas 105:528; Morvan et al (1990) Biochem Biophys Res Comm 172:537-543; Anderson et al. (1984) Nucleosides and Nucleotides 3:499-512; Asseline et al.
  • L-2'-deoxynucleosides dC and dU can be prepared readily from commercially available, naturally occurring L-arabinose (Anderson supra). Also, L-dU can be readily converted to L-dA and L-dG by transgleosylation procedures such as those detailed by Holy (1972) Collect Czech Chem Commun 37:4072-4087, and Spadari et al. (1992) J Med Chem 35:4214-4220; and L-thymidine can be synthesized from L-dU according to the procedure of Reese et al. (1983) J Chem Soc Chem 21
  • L-nucleosides such as the phosphoramidites of the nucleosides
  • L-RNA can be assembled in similar fashion using the silyl phosphoramidite method (OgUvie et al. (1988) PNAS 85:5764-5768; and Damha et al. (1993) in Protocols for Oligonucleotides and Analogs: Synthesis and Properties (Agrawal. S. Ed.) pp. 81-114, The Humana Press, Inc., Totowa, NJ).
  • the L-oligonucleotide targets can be used to screen L- peptide or other libraries for compounds which selectively bind a particular nucleic acid sequence or structure (such as a hairpin).
  • a particular nucleic acid sequence or structure such as a hairpin.
  • D-amino acid enantiomers of the peptides will accordingly bind the natural D-enantiomer of the nucleic acid.
  • Such compounds can be useful as, for example, specific inhibitors of transcriptional and/or translational events, or as agents which alter transcript stability.
  • the nucleic acid target can be, to illustrate, the L- enantiomer of a transcriptional regulatory sequence; a structural sequence, e.g., which involves histone contact or other chromatin regulatory processes; a methylation site; a viral RNA or DNA a 11 rRNA; a tRNA; or a sequence involved in mRNA stability, ribosome contact and/or critical 2° structure.
  • the nucleic acid target is the L-enantiomer of a single-stranded RNA with the HIN TAR sequence.
  • the TAR sequence through the formation of different 2° structures in the presence or absence of various factors (e.g.
  • TAT is a cis-acting element which regulates transcription of certain HIN genes.
  • molecules which alter the structure or equilibrium of structures of the TAR sequence may be useful to disrupt the fidelity of the HTV life cycle (Lepidof et al. (1995) J Virol 69:5422-5430; and U.S. Patents 5,474,935 and 5,278,042).
  • the subject method can be used to identify molecules which disrupt the TAR structure, or the ability of cellular or viral proteins to bind the TAR sequence.
  • D-peptides which may be useful in the treatment of HIN can be identified by the subject method.
  • the TAR sequence can be used to screen nucleic acid libraries in order to identify L-nucleic acids as potential antisense constructs (described infra); such nucleic acids may ultimately have therapeutic value.
  • the nucleic acid target is the L-enantiomer of the double-stranded D ⁇ A estrogen response element (ERE).
  • ERE double-stranded D ⁇ A estrogen response element
  • D-peptides which bind the ERE may prevent D ⁇ A binding of the estrogen receptor, thereby acting as anti- estrogens (REF).
  • the target can be a carbohydrate.
  • Carbohydrate can be synthesized from L-sugars, many of which are readily available, in order to provide the opposite enantiomer to a carbohydrate of interest.
  • step-wise synthesis of L-carbohydrates can be carried out using traditional organic synthesis (see, for example, Malikes et al. (1990) Chemiker-Zeitung 114:371-375; PCT publication WO 95/03315; and U.S. patents 5,476,924 and 5,470,843), and may be automated (see U.S. patent 5,288,037).
  • Carbohydrate targets can be polymeric, e.g. a polysaccharide, or constitute a portion of a non-polymeric molecule, such as an inositol.
  • the carbohydrate target will constitute a glycoconjugate, such as may be produced by condensation with a polyamide such as a polypeptide.
  • a polyamide such as a polypeptide.
  • the molecule(s) to which the carbohydrate is conjugated if chiral, may be provided in enantiomerically pure form as well. Accordingly, an L- polysaccharide and D-peptide can be coupled to form the opposite enantiomeric target for a given glycoprotein.
  • the carbohydrate target can be an L-polysaccharide enantiomer of a carbohydrate found on a cell surface receptor, or a viral protein, which are implicated in viral infectivity.
  • Ligands identified by the subject method may, accordingly, be useful to prevent viral infectivity.
  • exemplary chiral targets include, in addition to the polymers described above, non-peptide hormones and other small molecule signal transducers, metabolic products, and transition state analogs.
  • the target molecule can be an enantiomer of a prostaglandin or thromboxane.
  • enantioselective synthesis of thromboxanes are described in U.S. Patent 4,256,646.
  • Agents identified by the subject method which bind to prostaglandins or thromboxanes may be useful for modulating platelet aggregation.
  • the target can be the opposite enantiomer of a naturally occurring inositol.
  • Inositol phosphates are critical components in many signal transduction pathways. Inositol binding molecules identified by the subject method may be useful therefore as modulators of various signal processes, particularly in altering a cell's response to extracellular signals transduced by cell surface receptors.
  • the target molecule is the opposite enantiomer of a bioactive steroid, lipid-soluble vitamin, terpene or acetogenims.
  • Steroids are also critical components of intracellular and extracellular signaling.
  • Ligands which bind, for example, progesterone, aldosterone, cortisol, testosterone, and/or estradiol can have broad therapeutic application including modulation of inflammation and fertility.
  • Other potentially therapeutic compounds may be identified in the present method using, for example, enantiomerically-enriched preparations of any of vitamin K, vitamin E, vitamin vitamin D, Santonin, cedrol, gibberellic acid, citrinin, terramycin and the like as target proteins.
  • the target is an enantiomer of a chiral drug.
  • the enantioselective synthesis of cocaine has been previously described (Lewin et al. (1987) J Heterocyclic Chem 24:19).
  • peptides or other molecules from a library
  • the opposite enantiomer of the identified ligand which should bind the bioactive (-) cocaine, can be further tested for its ability to antagonize the delivery of cocaine to its receptor.
  • the target can be a transition state analog of a desired chemical reaction.
  • Molecules identified by the subject method can be tested for the ability to enhance, and even catalyze, a chemical reaction.
  • transition state analogs of cocaine have been synthesized from (-) ecgonine, and these analogs have successfully been employed to generate catalytic antibodies (see, for example, Landry et al. (1993) Science 259:1899-1901).
  • the enantiomer of the Landry transition state analog e.g. derived from (+) ecgonine, can be used to screen compound libraries. The enantiomers of such molecules can then be tested for catalytic activity in converting cocaine benzoyl ester to ecgonine methyl ester.
  • Such catalytic agents may be useful in the treatment of cocaine addiction
  • the target can be screened against any of a variety of test compounds.
  • the compound library can range from natural extracts to random chemical collections to combinatorial libraries.
  • the molecular identity of a test compound which interacts with the target can be readily ascertained.
  • the test compound may be present to such a concentration that it is directly sequenceable, such as by mass spectroscopy, or is immobilized at a known spatial address, or is associated with a label which provides the ability to either amplify the test agent and/or itself provides the information as to the molecular identity of the test agent.
  • Exemplary combinatorial libraries include peptide libraries, nucleic acid libraries, carbohydrate libraries, and libraries of small organic molecules. Other libraries amenable to the subject method, e.g. which contain many chiral compounds, will be apparent to those skilled in the art in light of the present invention.
  • the variegated peptide libraries of the subject method can be generated by any of a number of methods, and, though not limited by, preferably exploit recent trends in the preparation of chemical libraries.
  • the library can be prepared, for example, by either synthetic or biosynthetic approaches, and screened for activity against the D-enantiomer target in a variety of assay formats.
  • variant refers to the fact that a population of peptides is characterized by having a peptide sequence which differ from one member of the library to the next.
  • the tajal number of different pppTi ⁇ ftp sequences in the library is given by the product of ⁇ ⁇ V2 X " »V n -l x Vn *- " ere eac * 1 v n represents the number different amino acid residues occurring at position n of the peptide.
  • the peptide display collectively produces a peptide library including at least 96 to IO 7 different peptides, so that diverse peptides may be simultaneously assayed for the ability to interact with the target protein.
  • Peptide libraries are systems which simultaneously display, in a form which permits interaction with a target protein, a highly diverse and numerous collection of peptides. These peptides may be presented in solution (Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner USSN 5,223,409), spores (Ladner USSN '409), plasmids (Cull et al.
  • the peptide library is derived to express a combinatorial library of peptides which are not based on any known sequence, nor derived from cDNA. That is, the sequences of the library are largely random. It will be evident that the peptides of the library may range in size from dipeptides to large proteins.
  • the peptide library is derived to express a combinatorial library of peptides which are based at least in part on a known polypeptide sequence or a portion thereof (not a cDNA library). That is, the sequences of the library is semi- random, being derived by combinatorial mutagenesis of a known sequence(s). See, for example, Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffths et al. (1993) EMBOJ 12:725-734; Clackson et al.
  • polypeptid ) which are known ligands for a target protein can be mutagenized by standard techniques to derive a variegated library of polypeptide sequences which can further be screened for agonists and/or antagonists.
  • the combinatorial polypeptides are produced from a cDNA library.
  • the combinatorial peptides of the library can be generated as is, or can be incorporated into larger fusion proteins.
  • the fusion protein can provide, for example, stability against degradation or denaturation, as well as a secretion signal if secreted.
  • the polypeptide library is provided as part of thioredoxin fusion proteins (see, for example, U.S. Patents 5,270,181 and 5,292,646; and PCT publication WO94/ 02502).
  • the combinatorial peptide can be attached on the terminus of the thioredoxin protein, or, for short peptide libraries, inserted into the so- called active loop.
  • the combinatorial polypeptides are in the range of 3- 100 amino acids in length, more preferably at least 5-50, and even more preferably at least 10, 13, 15, 20 or 25 amino acid residues in length.
  • the polypeptides of the library are of uniform length. It will be understood that the length of the combinatorial peptide does not reflect any extraneous sequences which may be present in order to facilitate expression, e.g., such as signal sequences or invariant portions of a fusion protein.
  • the harnessing of biological systems for the generation of peptide diversity is now a well established technique which can be exploited to generate the peptide libraries of the subject method.
  • the source of diversity is the combinatorial chemical synthesis of mixtures of oligonucleotides. Oligonucleotide synthesis is a well-characterized chemistry that allows tight control of the composition of the mixtures created.
  • Degenerate DNA sequences produced are subsequently placed into an appropriate genetic context for expression as peptides. There are two principal ways in which to prepare the required degenerate mixture. In one method, the DNAs are synthesized a base at a time.
  • each trinucleotide being a codon of one (and only one) of the amino acids to be featured in the peptide library.
  • a mixture is made of the appropriate trinucleotides and reacted with the nascent DNA.
  • degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes can then be ligated into an appropriate gene for expression.
  • the purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential test peptide sequences.
  • the synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sy pos. Macromolecules, ed.
  • a variegated peptide library can be expressed by a population of display packages to form a peptide display library.
  • the display package on which the variegated peptide library is manifest it will be appreciated from the discussion provided herein that the display package will often preferably be able to be (i) genetically altered to encode a test peptide, (ii) maintained and amplified in culture, (iii) manipulated to display the peptide in a manner permitting the peptide to interact with a target protein during an affinity separation step, and (iv) affinity separated while retaining the peptide-encoding gene such that the sequence of the peptide can be obtained.
  • the display remains viable after affinity separation.
  • the display package comprises a system that allows the sampling of very large variegated peptide display libraries, rapid sorting after each affinity separation round, and easy isolation of the peptide-encoding gene from purified display packages.
  • the most attractive candidates for this type of screening are prokaryotic organisms and viruses, as they can be amplified quickly, they are relatively easy to manipulate, and large number of clones can be created.
  • Preferred display packages include, for example, vegetative bacterial cells, bacterial spores, and most preferably, bacterial viruses (especially DNA viruses).
  • the present invention also contemplates the use of eukaryotic cells, including yeast and their spores, as potential display packages.
  • kits for generating phage display libraries e.g. the Pharmacia Recombinant Phage Peptide System, catalog no. 27-9400-01; and the Stratagene SurfZAPTM phage display kit, catalog no. 240612
  • methods and reagents particularly amenable for use in generating the variegated peptide display library of the present method can be found in, for example, the Ladner et al. U.S. Patent No. 5,223,409; the Kang et al. International Publication No. WO 92/18619; the Dower et al. International Publication No. WO 91/17271; the Winter et al.
  • the display means of the package will comprise at least two components.
  • the first component is a secretion signal which directs the recombinant peptide to be localized on the extracellular side of the cell membrane (of the host cell when the display package is a phage). This secretion signal is characteristically cleaved off by a signal peptidase to yield a processed, "mature" peptide.
  • the second component is a display anchor protein which directs the display package to associate the peptide with its outer surface. As described below, tbis anchor protein can be derived from a surface or coat protein native to the genetic package.
  • the means for arraying the variegated peptide library comprises a derivative of a spore or phage coat protein amenable for use as a fusion protein.
  • the cloning site for the test peptide sequences in the phagemid should be placed so that it does not substantially interfere with normal phage function.
  • One such locus is the intergenic region as described by Zinder and Boeke, (1982) Gene 19:1-10.
  • the test peptide sequence is preferably expressed at an equal or higher-level than the H L .cpIH product (described below) to maintain a sufficiently high V L concentration in the periplasm and provide efficient assembly (association) of V L with V H chains.
  • a phagemid can be constructed to encode, as separate genes, both a V ⁇ /coat fusion protein and a V L chain. Under the appropriate induction, both chains are expressed and allowed to assemble in the periplasmic space of the host cell, the assembled peptide being linked to the phage particle by virtue of the VJJ chain being a portion of a coat protein fusion construct.
  • the number of possible peptides for a given library may, in certain instances, exceed 10 12 . To sample as many combinations as possible depends, in part, on the ability to recover large numbers of transformants.
  • electrotransformation provides an efficiency comparable to that of phage-transfection with in vitro packaging, in addition to a very high capacity for DNA input.
  • This allows large amounts of vector DNA to be used to obtain very large numbers of transformants.
  • the method described by Dower et al. (1988) Nucleic Acids Res., 16:6127-6145, for example, may be used to transform fd-tet derived recombinants at the rate of about IO 7 transformants/ug of ligated vector into E. coli (such as strain MC1061), and libraries may be constructed in fd-tet Bl of up to about 3 x IO 8 members or more.
  • Increasing DNA input and making modifications to the cloning protocol within the ability of the skilled artisan may produce increases of greater than about 10- fold in the recovery of transformants, providing libraries of up to 10 10 or more recombinants.
  • an important criteria for the present selection method can be that it is able to discriminate between peptides of different affinity for a particular target, and preferentially enrich for the peptides of highest affinity.
  • manipulating the display package to be rendered effectively monovalent can allow affinity enrichment to be carried out for generally higher binding affinities (i.e. binding constants in the range of IO 6 to 10 10 M' 1 ) as compared to the broader range of affinities isolable using a multivalent display package.
  • the natural i.e.
  • the library of display packages will comprise no more than 5 to 10% polyvalent displays, and more preferably no more than 2% of the display will be polyvalent , and most preferably, no more than 1% polyvalent display packages in the population.
  • the source of the wild-type anchor protein can be, for example, provided by a copy of the wild-type gene present on the same construct as the peptide fusion protein, or provided by a separate construct altogether.
  • Bacteriophage are attractive prokaryotic-related organisms for use in the subject method. Bacteriophage are excellent candidates for providing a display system of the variegated peptide library as there is little or no enzymatic activity associated with intact mature phage, and because their genes are inactive outside a bacterial host, rendering the mature phage particles metabolically inert. In general, the phage surface is a relatively simple structure. Phage can be grown easily in large numbers, they are 2b
  • the peptide gene is inserted into the phage genome, choosing the appropriate phage to be employed in the subject method will generally depend most on whether (i) the genome of the phage allows introduction of the peptide-encoding gene either by tolerating additional genetic material or by having replaceable genetic material; (ii) the virion is capable of packaging the genome after accepting the insertion or substitution of genetic material; and (iii) the display of the peptide on the phage surface does not disrupt virion structure sufficiently to interfere with phage propagation.
  • phage One concern presented with the use of phage is that the morphogenetic pathway of the phage determines the environment in which the peptide will have opportunity to fold. Periplasmically assembled phage are preferred as the displayed antibodies where the test peptide contains essential disulfides. However, in certain embodiments in which the display package forms intracellularly (e.g., where ⁇ phage are used), it has been demonstrated that the peptide may assume proper folding after the phage is released from the cell.
  • the preferred display means is a protein that is present on the phage surface (e.g. a coat protein).
  • Filamentous phage can be described by a helical lattice; isometric phage, by an icosahedral lattice.
  • Each monomer of each major coat protein sits on a lattice point and makes defined interactions with each of its neighbors. Proteins that fit into the lattice by making some, but not all, of the normal lattice contacts are likely to destabilize the virion by aborting formation of the virion as well as by leaving gaps in the virion so that the nucleic acid is not protected.
  • the peptide library is expressed and allowed to assemble in the bacterial cytoplasm, such as when the ⁇ phage is employed.
  • the induction of the protein(s) may be delayed until some replication of the phage genome, synthesis of some of the phage structural-proteins, and assembly of some phage particles has occurred.
  • the assembled protein chains then interact with the phage particles via the binding of the anchor protein on the outer surface of the phage particle.
  • the cells are lysed and the phage bearing the library-encoded test peptides (that correspond to the specific library sequences carried in the DNA of that phage) are released and isolated from the bacterial debris.
  • phage harvested from the bacterial debris are, for example, affinity purified.
  • the target protein can be used to retrieve phage displaying the desired peptide.
  • the phage so obtained may then be amplified by infecting into host cells. Additional rounds of affinity enrichment followed by amplification may be employed until the desired level of enrichment is reached.
  • the enriched peptide-phage can also be screened with additional detection- techniques such as expression plaque (or colony) lift (see, e.g., Young and Davis, Science (1983) 222:778-782) whereby a labeled target protein is used as a probe.
  • additional detection- techniques such as expression plaque (or colony) lift (see, e.g., Young and Davis, Science (1983) 222:778-782) whereby a labeled target protein is used as a probe.
  • the phage obtained from the screening protocol are infected into cells, propagated, and the phage DNA isolated and sequenced, and/or recloned into a vector intended for gene expression in prokaryotes or eukaryotes to obtain larger amounts of the particular peptide selected.
  • the peptide is also transported to an extra- cytoplasmic compartment of the host cell, such as the bacterial periplasm, but as a fusion protein with a viral coat protein.
  • the desired protein or one of its polypeptide chains if it is a multichain peptide
  • the viral coat protein which is processed and transported to the cell inner membrane.
  • Other chains, if present, are expressed with a secretion leader and thus are also transported to the periplasm or other intracellular by extra-cytoplasmic location. The chains present in the extra- cytoplasm then assemble into a complete test peptide.
  • the assembled molecules become incorporated into the phage by virtue of their attachment to the phage coat protein as the phage extrude through the host membrane and the coat proteins assemble around the phage DNA.
  • the phage bearing the test peptide may then be screened by affinity enrichment as described below.
  • Filamentous bacteriophages which include Ml 3, fl, fd, Ifl, Dee, Xf, Pfl, and Pf3, are a group of related viruses that infect bacteria. They are termed filamentous because they are long, thin particles comprised of an elongated capsule that envelopes the deoxyribonucleic acid (DNA) that forms the bacteriophage genome.
  • the F pili filamentous bacteriophage (Ff phage) infect only gram-negative bacteria by specifically adsorbing to the tip of F pili, and include fd, fl and Ml 3.
  • filamentous phage in general are attractive for generating the peptide libraries of the subject method, and Ml 3 in particular is especially attractive because: (i) the 3-D structure of the virion is known; (ii) the processing of the coat protein is well understood; (iii) the genome is expandable; (iv) the genome is small; (v) the sequence of the genome is known; (vi) the virion is physically resistant to shear, heat, cold, urea, guanidinium chloride, low pH, and high salt; (vii) the phage is a sequencing vector so that sequencing is especially easy; (v ⁇ i) antibiotic-resistance genes have been cloned into the genome with predictable results (Hines et al.
  • M13 is a plasmid and transformation system in itself, and an ideal sequencing vector. Ml 3 can be grown on Ree- strains of £ coli. The M13 genome is expandable (Messing et al. in The Single-Stranded DNA Phages, eds Denhardt et al. (NY: CSHL Press, 1978) pages 449-453; and Fritz et al., supra) and M13 does not lyse cells. Extra genes can be inserted into M13 and will be maintained in the viral genome in a stable manner.
  • the mature capsule or Ff phage is comprised of a coat of five phage-encoded gene products: cpVUI, the major coat protein product of gene VUI that forms the bulk of the capsule; and four minor coat proteins, cpDI and cpJN at one end of the capsule and cpVH and cpLX at the other end of the capsule.
  • the length of the capsule is formed by 2500 to 3000 copies of cp VUI in an ordered helix array that forms the characteristic filament structure.
  • the gene JJI-encoded protein (cpILI) is typically present in 4 to 6 copies at one end of the capsule and serves as the receptor for binding of the phage to its bacterial host in the initial phase of infection.
  • the phage particle assembly involves extrusion of the viral genome through the host cell's membrane.
  • the major coat protein cpVJH and the minor coat protein cpEQ are synthesized and transported to the host cell's membrane.
  • Both cpVUI and cpIH are anchored in the host cell membrane prior to their incorporation into the mature particle.
  • the viral genome is produced and coated with cpV protein.
  • cpV-coated genomic D ⁇ A is stripped of the cpV coat and simultaneously recoated with the mature coat proteins.
  • Both cpHI and cpVUI proteins include two domains that provide signals for assembly of the mature phage particle.
  • the first domain is a secretion signal that directs the newly synthesized protein to the host cell membrane.
  • the secretion signal is located at the amino terminus of the polypeptide and targets the polypeptide at least to the cell membrane.
  • the second domain is a membrane anchor domain that provides signals for association with the host cell membrane and for association with the phage particle during assembly. This second signal for both cpVUI and cpJJI comprises at least a hydrophobic region for spanning the membrane.
  • the 50 amino acid mature gene VUI coat protein (cp UI) is synthesized as a 73 amino acid precoat (lto et al. (1979) PNAS 76:1199-1203).
  • the cpVUI protein has been extensively studied as a model membrane protein because it can integrate into lipid bilayers such as the cell membrane in an asymmetric orientation with the acidic amino terminus toward the outside and the basic carboxy terminus toward the inside of the membrane.
  • the first 23 amino acids constitute a typical signal-sequence which causes the nascent polypeptide to be inserted into the inner cell membrane.
  • SP-I signal peptidase
  • the sequence of gene V ⁇ i is known, and the amino acid sequence can be encoded on a synthetic gene.
  • Mature gene VUI protein makes up the sheath around the circular ssDNA.
  • the gene VUI protein can be a suitable anchor protein because its location and orientation in the virion are known (Banner et al. (1981) Nature 289:814- 816).
  • the test peptide is attached to the amino terminus of the mature M13 coat protein to generate the phage display library.
  • manipulation of the concentration of both the wild-type cpVHI and test peptide/cpVUI fusion in an infected cell can be utilized to decrease the avidity of the display and thereby enhance the detection of high affinity antibodies directed to the target epitop ).
  • test peptide library Another vehicle for displaying the test peptide library is by expressing it as a domain of a chimeric gene containing part or all of gene HI.
  • expressing the test peptide as a fusion protein with cpHI can be a preferred embodiment, as manipulation of the ratio of wild-type gpUI to chimeric cpHI during formation of the phage particles can be readily controlled.
  • This gene encodes one of the minor coat proteins of Ml 3.
  • the single-stranded circular phage DNA associates with about five copies of the gene HI protein and is then extruded through the patch of membrane-associated coat protein in such a way that the DNA is encased in a helical sheath of protein (Webster et al. in The Single-Stranded DNA Phages, eds Dressier et al. (NY:CSHL Press, 1978).
  • test peptide-encoding gene may be fused to gene DI at the site used by Smith and by de la Cruz et al., e.g., at a codon corresponding to another domain boundary or to a surface loop of the protein, or to the amino terminus of the mature protein.
  • Pf3 is a well known filamentous phage that infects Pseudomonas aerugenosa cells that harbor an IncP-I plasmid.
  • the entire genome has been sequenced ((Luiten et al. (1985) J. Virol. 56:268-276) and the genetic signals involved in replication and assembly are known (Luiten et al. (1987) DNA 6:129-137).
  • the major coat protein of PF3 is unusual in having no signal peptide to direct its secretion. The sequence has charged residues ASP-7, ARG-37, LYS-40, and PHE44 which is consistent with the amino terminus being exposed.
  • a tripartite gene can be constructed which comprises a signal sequence known to cause secretion in P. aerugenosa, fused in-frame to a gene fragment encoding the test peptide sequence, which is fused in-frame to DNA encoding the mature Pf3 coat protein.
  • DNA encoding a flexible linker of one to 10 amino acids is introduced between the test peptide fragment and the Pf3 coat-protein gene. This tripartite gene is introduced into Pf3. Once the signal sequence is cleaved off, the test peptide is in the periplasm and the mature coat protein acts as an anchor and phage-assembly signal.
  • the bacteriophage ⁇ X174 is a very small icosahedral virus which has been thoroughly studied by genetics, biochemistry, and electron microscopy (see The Single Stranded DNA Phages (eds. Den hardt et al. (NY:CSHL Press, 1978)).
  • Three gene products of ⁇ X174 are present on the outside of the mature virion: F (capsid), G (major spike protein, 60 copies per virion), and H (minor spike protein, 12 copies per virion).
  • the G protein comprises 175 amino acids, while H comprises 328 amino acids.
  • the F protein interacts with the single-stranded DNA of the virus.
  • the proteins F, G, and H are translated from a single mRNA in the viral infected cells.
  • ⁇ X174 is not typically used as a cloning vector due to the fact that it can accept very little additional DNA.
  • mutations in the viral G gene can be rescued by a copy of the wild-type G gene carried on a plasmid that is expressed in the same host cell (Chambers et al. (1982) Nuc Acid Res 10:6465-6473).
  • one or more stop codons are introduced into the G gene so that no G protein is produced from the viral genome.
  • Nucleic acid encoding the variegated peptide library can then be fused with the nucleic acid sequence of the H gene.
  • the second plasmid can further include one or more copies of the wild-type H protein gene so that a mix of H and test peptide/H proteins will be predominated by the wild- type H upon inco ⁇ oration into phage particles.
  • Phage such as ⁇ or T4 have much larger genomes than do Ml 3 or ⁇ X174, and have more complicated 3-D capsid structures than M13 or ⁇ PX174, with more coat proteins to choose from.
  • bacteriophage ⁇ and derivatives thereof are examples of suitable vectors.
  • the intracellular morphogenesis of phage ⁇ can potentially prevent protein domains that ordinarily contain disulfide bonds from folding correctly.
  • Recombinant peptides are able to cross bacterial membranes after the addition of bacterial leader sequences to the peptides (Better et al (1988) Science 240: 1041-1043; and Skerra et al. (1988) Science 240:1038-1041). Di addition, recombinant peptides have been fused to outer membrane proteins for surface presentation. Accordingly, one strategy for displaying test peptides on bacterial cells comprises generating a fusion protein by adding the test peptide to cell surface exposed portions of an integral outer membrane protein (Fuchs et al. (1991) Bio/Technology 9:1370-1372).
  • any well-characterized bacterial strain will typically be suitable, provided the bacteria may be grown in culture, engineered to display the peptide library on its surface, and is compatible with the particular affinity selection process practiced in the subject method.
  • the preferred display systems include Salmonella typhirnurium, Bacillus subtilis, Pseudomonas aeruginosa, Vibrio cholerae, Klebsiella pneumonia, Neisseria gonorrhoeae, Neisseria meningitidis, Bacteroides nodosus, Moraxella bovis, and especially Escherichia coli.
  • LamB protein of E coli is a well understood surface protein that can be used to generate a variegated library of test peptides (see, for example, Ronco et al. (1990) Biochemie 72: 183-189; van der Weit et al. (1990) Vaccine 8:269-277; Charabit et al. (1988) Gene 70:181-189; and Ladner U.S. Patent No. 5,222,409).
  • LamB of E. coli is a porin for maltose and maltodextrin transport, and serves as the receptor for adsorption of bacteriophages ⁇ and K10.
  • LamB is transported to the outer membrane if a functional N-terminal signal sequence is present (Benson et al. (1984) PNAS 81:3830-3834). As with other cell surface proteins, LamB is synthesized with a typical signal-sequence which is subsequently removed.
  • the variegated peptide-encoding gene library can be cloned into the LamB gene such that the resulting library of fusion proteins comprise a portion of LamB sufficient to anchor the protein to the cell membrane with the test peptide portion oriented on the extracellular side of the membrane. Secretion of the extracellular portion of the fusion ⁇
  • LamB signal sequence or other suitable signal sequence, as the N-terminus of the protein.
  • the E. coli LamB has also been expressed in functional form in S. typhimurium (Harkki et al. (1987) Mol Gen Genet 209:607-611), V. cholerae (Harkki et al. (1986) Microb Pathol 1:283-288), and K. pneumonia (Wehmeier et al. (1989) Mol Gen Genet 215:529-536), so that one could display a population of test peptides in any of these species as a fusion to E. coli LamB. Moreover, K. pneumonia expresses a maltoporin similar to LamB which could also be used. In P.
  • the Dl protein (a homologue of LamB) can be used (Trias et al. (1988) Biochem Biophys Acta 938:493- 496).
  • other bacterial surface proteins such as PAL, OmpA, OmpC, OmpF, PhoE, pilin, BtuB, FepA, FhuA, IutA, FecA and FhuE, may be used in place of LamB as a portion of the display means in a bacterial cell.
  • Bacterial spores also have desirable properties as display package candidates in the subject method. For example, spores are much more resistant than vegetative bacterial cells or phage to chemical and physical agents, and hence permit the use of a great variety of affinity selection conditions. Also, Bacillus spores neither actively metabolize nor alter the proteins on their surface. However, spores have the disadvantage that the molecular mechanisms that trigger sporulation are less well worked out than is the formation of M13 or the export of protein to the outer membrane of £. coli, though such a limitation is not a serious detractant from their use in the present invention
  • Bacteria of the genus Bacillus form endospores that are ' extremely resistant to damage by heat, radiation, desiccation, and toxic chemicals (reviewed by Losick et al. (1986) Ann Rev Genet 20:625-669). This phenomenon is attributed to extensive intermolecular cross-linking of the coat proteins. In certain embodiments of the subject method, such as those which include relatively harsh affinity separation steps, such spores can be the preferred display package. Endospores from the genus Bacillus are more stable than are, for example, exospores from Streptomyces. Moreover, Bacillus subtilis forms spores in 4 to 6 hours, whereas Streptomyces species may require days or weeks to sporulate. In addition, genetic knowledge and manipulation is much more developed for B. subtilis than for other spore-forming bacteria.
  • in vitro chemical synthesis provides a method for generating libraries of compounds, without the use of living organisms, that can be screened for ability to bind to a target protein.
  • in vitro methods have been used for quite some time in the pharmaceutical industry to identify potential drugs, recently developed methods have focused on rapidly and efficiently generating and screening large numbers of compounds and are particularly amenable to generating peptide libraries for use in the subject method.
  • the various approaches to simultaneous preparation and analysis of large numbers of synthetic peptides (herein “multiple peptide synthesis" or "MPS”) each rely on the fundamental concept of synthesis on a solid support introduced by Merrifield in 1963 (Merrifield, R.B.
  • peptide library of the subject method can take is the multipin library format.
  • Geysen and co-workers introduced a method for generating peptide by a parallel synthesis on polyacrylic acid-grated polyethylene pins arrayed in the microtitre plate format.
  • about 50 nmol of a single peptide sequence was covalently linked to the spherical head of each pin, and interactions of each peptide with receptor or antibody could be determined in a direct binding assay.
  • the Geysen technique can be used to synthesize and screen thousands of peptides per week using the multipin method, and the tethered peptides may be reused in many assays.
  • the level of peptide loading on individual pins has been increased to as much as 2 ⁇ mol/pin by grafting greater amounts of functionalized acrylate derivatives to detachable pin heads, and the size of the peptide library has been increased (Valerio et al. (1993) Int J Pept Protein Res 42:1-9).
  • a variegated library of peptides can provide on a set of beads utilizing the strategy of divide-couple-recombine (see, e.g., Houghten (1985) PNAS 82:5131-5135; and U.S. Patents 4,631,211; 5,440,016; 5,480,971). Briefly, as the name implies, at each synthesis step where degeneracy is introduced into the library, the beads are divided into as many separate groups to correspond to the number of different amino acid residues to be added that position, the different residues coupled in separate reactions, and the beads recombined into one pool for the next step.
  • the divide-couple-recombine strategy can be carried out using the so-called "tea bag” MPS method first developed by Houghten, peptide synthesis occurs on resin that is sealed inside porous polypropylene bags (Houghten et al. (1986) PNAS 82:5131-5135). Amino acids are coupled to the resins by placing the m
  • each bag contains a single peptide sequence, and the peptides may be liberated from the resins using a multiple cleavage apparatus (Houghten et al. (1986) Int J Pept Protein Res 27:673- 678). This technique offers advantages of considerable synthetic flexibility and has been partially automated (Beck-Sickinger et al. (1991) Pept Res 4:88-94). Moreover, soluble peptides of greater than 15 amino acids in length can be produced in sufficient quantities (>. 500 ⁇ mol) for purification and complete characterization if desired.
  • DDSA diisopropylethylamine
  • CH 2 C1 2 DCM
  • the bags are then rinsed with DCM and placed into separate reaction vessels each containing 50 ml (0.56M) of the respective t- BOC-amino acid/DCM.
  • N,N-Diisopropylcarbodiimide (DffCDI; 25 ml; 1.12M) is added to each container, as a coupling agent.
  • Twenty amino acid derivatives are separately coupled to the resin in 50/50 (v/v) DMF/DCM. After one hour of vigorous shaking, Gisen's picric acid test (Gisen (1972) Anal. Chem. Acta 58:248-249) is performed to determine the completeness of the coupling reaction.
  • the polypropylene bags are kept separated to here provide the twenty sets having the amino- terminal residue as the single, predetermined residue, with, for example, positions 2-4 being occupied by equimolar amounts of the twenty residues.
  • the contents of the bags are not mixed after adding a residue at the desired, predetermined position. Rather, the contents of each of the twenty bags are separated into 20 aliquots, deprotected and then separately reacted with the twenty amino acid derivatives. The contents of each set of twenty bags thus produced are thereafter mixed and treated as before-described until the desired oligopeptide length is achieved.
  • a scheme of combinatorial synthesis in which the identity of a compound is given by its locations on a synthesis substrate is termed a spatially-addressable synthesis.
  • the combinatorial process is carried out by controlling the addition of a chemical reagent to specific locations on a solid support (Dower et al. (1991) Annu Rep Med Chem 26:271-280; Fodor, S P A. (1991) Science 251:767; Pirrung et al. (1992) U.S. Patent No. 5,143,854; Jacobs et al. (1994) Trends Biotechnol 12: 19-26).
  • the technique combines two well-developed technologies: solid-phase peptide synthesis chemistry and photolithography.
  • the high coupling yields of Merrifield chemistry allow efficient peptide synthesis, and the spatial resolution of photolithography affords miniaturization.
  • the merging of these two technologies is done through the use of photolabile amino protecting groups in the Merrifield synthetic procedure.
  • a synthesis substrate is prepared for amino acid coupling through the covalent attachment of photolabile nitroveratryloxycarbonyl (NVOC) protected amino linkers.
  • Light is used to selectively activate a specified region of the synthesis support for coupling. Removal of the photolabile protecting groups by lights (deprotection) results in activation of selected areas. After activation, the first of a set of amino acids, each bearing a photolabile protecting group on the amino terminus, is exposed to the entire surface. Amino acid coupling only occurs in regions that were addressed by light in the preceding step.
  • the solution of amino acid is removed, and the substrate is again illuminated through a second mask, activating a different region for reaction with a second protected building block.
  • the pattern of masks and the sequence of reactants define the products and their locations. Since this process utilizes photolithography techniques, the number of compounds that can be synthesized is limited only by the number of synthesis sites that can be addressed with appropriate resolution. The position of each compound is precisely known; hence, its interactions with other molecules can be directly assessed.
  • the target protein can be labeled with a fluorescent reporter group to facilitate the identification of specific interactions with individual members of the matrix. In a light-directed chemical synthesis, the products depend on the pattem of illumination and on the order of addition of reactants. By varying the lithographic patterns, many different sets of test peptides can be synthesized in the same number of steps; this leads to the generated of many different masking strategies.
  • the subject method utilizes a peptide library provided with an encoded tagging system.
  • a recent improvement in the identification of active compounds from combinatorial libraries employs chemical indexing systems using tags that uniquely encode the reaction steps a given bead has undergone and, by inference, the structure it carries.
  • this approach mimics phage display libraries above, where activity derives from expressed peptides, but the structures of the active peptides are deduced from the corresponding genomic DNA sequence.
  • the first encoding of synthetic combinatorial libraries employed DNA as the code. Two forms of encoding have been reported, encoding with sequenceable bio-oligomers (e.g., oligonucleotides and peptides), and binary encoding with non-sequenceable tags.
  • a combinatorial library of nominally 7 7 ( 823,543) peptides composed of all combinations of Arg, Gin, Phe, Lys, Val, D-Val and Thr (three-letter amino acid code), each of which was encoded by a specific dinucleotide (TA, TC, CT, AT, TT, CA and AC, respectively), was prepared by a series of alternating rounds of peptide and oligonucleotide synthesis on solid support.
  • the amine linking functionality on the bead was specifically differentiated toward peptide or oligonucleotide synthesis by simultaneously preincubating the beads with reagents that generate protected OH groups for oligonucleotide synthesis and protected NH 2 groups for peptide synthesis (here, in a ratio of 1:20).
  • the tags each consisted of 69-mers, 14 units of which carried the code.
  • the bead-bound library was incubated with a fluorescently labeled antibody, and beads containing bound antibody that fluoresced strongly were harvested by fluorescence-activated cell sorting (FACS).
  • FACS fluorescence-activated cell sorting
  • the peptide libraries can be derived for use in the subject method and screened using the D-enantiomer of the target protein.
  • an alternative approach useful for generating nucleotide-encoded synthetic peptide libraries employs a branched linker containing selectively protected OH and NH 2 groups (Nielsen et al. (1993) J Am Chem Soc 115:9812-9813; and Nielsen et al. (1994) Methods Compan Methods Enzymol 6:361-371).
  • This approach requires that equimolar quantities of test peptide and tag co-exist, though this may be a potential complication in assessing biological activity, especially with nucleic acid based targets.
  • oligonucleotide tags permits extremelyly sensitive tag analysis. Even so, the method requires careful choice of orthogonal sets of protecting groups required for alternating co-synthesis of the tag and the library member. Furthermore, the chemical lability of the tag, particularly the phosphate and sugar anomeric linkages, may limit the choice of reagents and conditions that can be employed for the synthesis on non- oligomeric libraries.
  • the libraries employ linkers permitting selective detachment of the test peptide library member for bioassay, in part (as described infra) because assays employing beads limit the choice of targets, and in part because the tags are potentially susceptible to biodegradation.
  • branched linkers are employed so that the coding unit and the test peptide are both attached to the same functional group on the resin.
  • a linker can be placed between the branch point and the bead so that cleavage releases a molecule containing both code and ligand (Ptek et al. (1991) Tetrahedron Lett 32:3891-3894).
  • the linker can be placed so that the test peptide can be selectively separated from the bead, leaving the code behind. This last construct is particularly valuable because it permits screening of the test peptide without potential interference, or biodegradation, of the coding groups. Examples in the art of independent cleavage and sequencing of peptide library members and their corresponding tags has confirmed that the tags can accurately predict the peptide structure.
  • peptide tags are more resistant to decomposition during ligand synthesis than are oligonucleotide tags, but they must be employed in molar ratios nearly equal to those of the ligand on typical 130 ⁇ m beads in order to be successfully sequenced.
  • oligonucleotide encoding the use of peptides as tags requires complex protection/deprotection chemistries.
  • Non-sequenceable tagging binary encoding
  • An alternative form of encoding the test peptide library employs a set of non- sequenceable electrophone tagging molecules that are used as a binary code (Ohlmeyer et al. (1993) PNAS 90:10922-10926).
  • Exemplary tags are haloaromatic alkyl ethers that are detectable as their tetramethylsilyl ethers at less than femtomolar levels by electron capture gas chromatography (ECGC).
  • ECGC electron capture gas chromatography
  • the tags were bound to about 1% of the available amine groups of a peptide library via a photocleavable O-nitrobenzyl linker. This approach is convenient when preparing combinatorial libraries of peptides or other am e-containing molecules.
  • a more versatile system has, however, been developed that permits encoding of essentially any combinatorial library.
  • the ligand is attached to the solid support via the photocleavable linker and the tag is attached through a catechol ether linker via carbene insertion into the bead matrix (Nestler et al. (1994) J Org Chem 59:4723-4724).
  • This orthogonal attachment strategy permits the selective detachment of library members for bioassay in solution and subsequent decoding by ECGC after oxidative detachment of the tag sets.
  • Binary encoding with electrophoric tags has been particularly useful in defining selective interactions of substrates with synthetic receptors (Borchardt et al. (1994) J Am Chem Soc 116:373-374), and model systems for understanding the binding and catalysis of biomolecules. Even using detailed molecular modelmg, the identification of the selectivity preferences for synthetic receptors has required the manual synthesis of dozens of potential substrates.
  • the use of encoded libraries makes it possible to rapidly examine all the members of a potential binding set.
  • the use of binary-encoded libraries has made the determination of binding selectivities so facile that structural selectivity has been reported for four novel synthetic macrobicyclic and tricyclic receptors in a single communication (Wennemers et al.
  • Both libraries were constructed using an orthogonal attachment strategy in which the library member was linked to the solid support by a photolabile linker and the tags were attached through a linker cleavable only by vigorous oxidation. Because the library members can be repetitively partially photoeluted from the solid support, library members can be utilized in multiple assays. Successive photoelution also permits a very high throughput iterative screening strategy: first, multiple beads are placed in 96-well microtiter plates; second, ligands are partially detached and transferred to assay plates; third, a bioassay identifies the active wells; fourth, the corresponding beads are rearrayed singly into new microtiter plates; fifth, single active compounds are identified; and sixth, the structures are decoded.
  • the library is comprised of a variegated pool of nucleic acids, e.g. single or double-stranded DNA or ARNA.
  • nucleic acids e.g. single or double-stranded DNA or ARNA.
  • a variety of techniques are known in the art for generating screenable nucleic acid libraries which may be exploited in the present invention.
  • many of the techniques described above for synthetic peptide libraries can be used to generate nucleic acid libraries of a variety of formats. For example, divide-couple-recombine techniques can be used in conjugation S3
  • solution libraries of nucleic acids can be generated which rely on PCR techniques to amplify for sequencing those nucleic acid molecules which selectively bind the screening target.
  • libraries approaching IO 15 different nucleotide sequences have been generated in solution (see, for example, Bartel and Szostak (1993) Science 261:1411-1418; Bock et al. (1992) Nature 355:564; Ellington et al. (1992) Nature 355:850-852; and Oliphant et al. (1989) Mol Cell Biol 9:2944-2949).
  • the SELEX systematic evolution of ligands by exponential enrichment
  • nucleic acid library is applied to screening a target, and nucleic acids which selectively bind (or otherwise act on the target) are isolated from the pool, the isolates are amplified by PCR and subcloned into, for example, phagemids. The phagemids are then transfected into bacterial cells, and individual isolates can be obtained and the sequence of the nucleic acid cloned from the screening pool can be determined.
  • RNA is the test ligand
  • the RNA library can be directly synthesized by standard organic chemistry, or can be provided by in vitro translation as described by Tuerk et al., supra.
  • RNA isolated by binding to the screening target can be reverse transcribed and the resulting cDNA subcloned and sequenced as above.
  • the library can be provided as a mixture of carbohydrates.
  • most sugars which make up carbohydrates are D- sugars and are readily available and/or easily synthesized.
  • the synthesis of polysaccharides has been rapidly advanced in recent years, both by direct chemical synthesis and by in vitro enzyme-mediated synthesis of polysaccharide.
  • the carbohydrate library can be generated in any of a number of formats.
  • the carbohydrates can be provided free in solution or immobilized to insoluble supports.
  • the members of the library can be derived with separate tags encoding their identity, or other deconvolution and/or detection methods can be used to identify those carbohydrate ligands isolated from a library by the subject method.
  • the oligosaccharide is provided on a solid support and synthesized by step-wise reactions.
  • a first sugar can be attached to the support at its reducing end.
  • the glycosyl acceptor is linked to the solid phase and coupling occurs with a solution-based donor.
  • a unique acceptor hydroxyl must be exposed in the solid phase. This requires the donor used in the previous glycosidation to be furnished with a uniquely deprotectable blocking group (-OP) at the site of elongation (Danishefsky et al. (1993) Science 260:1307-1309).
  • -OP uniquely deprotectable blocking group
  • Such synthesis strategies can be carried out, for example, in a divide- couple-recombine format as described above to yield a variegated library of beads where each individual bead is homogenous with respect to the oligosaccharide type it supports.
  • the carbohydrate library can be provided free in solution and deconvolution techniques employed to identify those members of solution library which bind to the target.
  • glycals can be used in the solution synthesis of oligosaccharide ensembles (Suzuki et al. (1990) J Am Chem Soc 112:8895; and Danishefsky et al. (1992) JAm Chem Soc 114:8329). Briefly, the glycals offer the advantage of ease in differential protection. To illustrate one exemplary synthesis, a glycal is activated by conversion to an epoxide, such as by treatment with
  • the carbohydrate library because it consists of the D- sugars, can be isolated from natural sources, e.g. such as from cells in culture.
  • the carbohydrate library can also be provided in the form of glycopeptides.
  • Ruberge et al. Science 269:202-204 describes a convergent synthesis approach to generating glycopeptides utilizing the epoxide activated glycals describe above. According to this method, combinatorial libraries in which the carbohydrate moiety is varied, or in which both the carbohydrate and peptide moieties are varied are contemplated.
  • the subject method is envisaged with a variety of detection methods for isolating and identifying compounds which interact with the screening target.
  • the screening programs which test libraries of compounds will be derived for high throughput analysis in order to maximize the number of compounds surveyed in a given period of time.
  • the screening portion of the subject method involves contacting the screening target with the compound library and isolating those compounds from the library which interact with the screening target.
  • Such interaction may be detected, for example, based on directly detecting the binding of the compounds to the screening target, or inferred through the modulation of interactions involving the screening target with other molecules, such as protein-protein or protein-DNA interaction involving the screening target or modulation of an enzymatic/catalytic activity of the screening target.
  • the efficacy of the test compounds can be assessed by generating dose response curves from data obtained using various concentrations of the test compound.
  • a control assay can also be performed to provide a baseline for comparison.
  • Complex formation between a test compounds and a screening target may be directly detected by a variety of techniques.
  • the complexes can be scored for using, for example, detectably labeled compounds or screening targets, such as radiolabeled, fluorescently labeled, or enzymatically labeled polypeptides, by immunoassay, or by chromatographic detection.
  • the variegated compound library is subjected to affinity enrichment in order to select for compounds which bind a preselected screening target.
  • affinity separation or “affinity enrichment” includes, but is not limited to (1) affinity chromatography utilizing immobilizing screening targets, (2) precipitation using screening targets, (3) fluorescence activated cell sorting where the compound library is so amenable, (4) agglutination, and (5) plaque lifts.
  • the library of compounds are ultimately separated based on the ability of a particular compound to bind a screening target of interest. See, for example, the Ladner et al. U.S. Patent No. 5,223,409; the Kang et al. International Publication No.
  • affinity chromatography it will be generally understood by those skilled in the art that a great number of chromatography techniques can be adapted for use in the present invention, ranging from column chromatography to batch elution, and including ELISA and reverse biopanning techniques.
  • the screening target is immobilized on an insoluble carrier, such as sepharose or polyacrylamide beads, or, alternatively, the wells of a microtitre plate.
  • the population of compounds is applied to the affinity matrix under conditions compatible with the binding of compounds in the library to the immobilized screening target.
  • the population is then fractionated by washing with a solute that does not greatly effect specific binding of compounds to the screening target, but which substantially disrupts any non-specific binding of components the library to the screening target or matrix.
  • a certain degree of control can be exerted over the binding characteristics of the compounds recovered from the library by adjusting the conditions of the binding incubation and subsequent washing.
  • the temperature, pH, ionic strength, divalent cation concentration, and the volume and duration of the washing can select for compounds within a particular range of affinity and specificity. Selection based on slow dissociation rate, which is usually predictive of high affinity, is a very practical route.
  • affinities of some compounds may be dependent on ionic strength or cation concentration.
  • Specific examples are peptides which depend on Ca 4-1" or other ions for binding activity and which release from the screening target in the presence of a chelating agent such as EGTA. (see, Hopp et al. (1988) Biotechnology 6:1204-1210). Such peptides may be identified in the compound library by a double screening technique isolating first those that bind the screening target in the presence of Ca -1" *, and by subsequently identifying those in this group that fail to bind in the presence of EGTA.
  • specifically compounds can be eluted by either specific desorption (using excess screening target) or non-specific deso ⁇ tion (using pH, polarity reducing agents, or chaotropic agents).
  • the elution protocol does not kill the organism used as the display package such that the enriched population of display packages can be further amplified by reproduction.
  • the list of potential eluants includes salts (such as those in which one of the counter ions is Na + , NH4+ Rb + , SO4 2 -, H 2 PO 4 -, citrate, K+ Li + , Cs+, HSO4-, CO 3 2 ", Ca 2+ , Sr 2 + CL-, PO4 2 -, HCO3-, Mg 2 + , Ba 2 + , Br, HPO4 2 -, or acetate), acid, heat, and, when available, soluble forms of the target antigen (or analogs thereof).
  • salts such as those in which one of the counter ions is Na + , NH4+ Rb + , SO4 2 -, H 2 PO 4 -, citrate, K+ Li + , Cs+, HSO4-, CO 3 2 ", Ca 2+ , Sr 2 + CL-, PO4 2 -, HCO3-, Mg 2 + , Ba 2 + , Br, HPO4 2 -, or
  • buffer components especially eluates
  • Neutral solutes such as ethanol, acetone, ether, or urea, are examples of other agents useful for eluting the bound display packages.
  • affinity enriched packages or nucleic acids are iteratively amplified and subjected to further rounds of affinity separation until enrichment of the desired binding activity is detected.
  • the specifically bound biological display packages especially bacterial cells, need not be eluted per se, but rather, the matrix bound display packages can be used directly to inoculate a suitable growth media for amplification.
  • the display package is a phage particle
  • the fusion protein generated with the coat protein can interfere substantially with the subsequent amplification of eluted phage particles, particularly in embodiments wherein the cpJH protein is used as the display anchor.
  • the peptide can be derived on the surface of the display package so as to be susceptible to proteolytic cleavage which severs the covalent linkage of at least the antigen binding sites of the displayed peptide from the remaining package.
  • such a strategy can be used to obtain infectious phage by treatment with an enzyme which cleaves between the peptide portion and cpJH portion of a tail fiber fusion protein (e.g. such as the use of an enterokinase cleavage recognition sequence).
  • DNA prepared from the eluted phage can be transformed into host cells by electroporation or well known chemical means.
  • the cells are cultivated for a period of time sufficient for marker expression, and selection is applied as typically done for DNA transformation.
  • the colonies are amplified, and phage harvested for a subsequent round(s) of panning.
  • the nucleic acid encoding the peptide for each of the purified display packages can be recloned in a suitable eukaryotic or prokaryotic expression vector and transfected into an appropriate host for production of large amounts of protein.
  • the isolated peptides are identified either directly from the display, e.g., by direct microsequencing, or the display packages are appropriately decoded, e.g., by elucidating the identity of an associated tag/index. Deconvolution techniques are also known in the art.
  • compound libraries can be fractionated based on other activities of the target molecule, such as modulation of catalytic activity.
  • D-GRP 27-amino-acid human GRP
  • Biotinyl-GGVPLPAGGGTVLTKMYPRGNHWAVGHLM-NH 2 (all D-amino acids)
  • the amino terminus was chosen for biotinylation because it is unnecessary for bombesin receptor binding (Cuttitta et al. (1985) Nature 316:823).
  • B-D-neuRL2 As with D-GRP, the eight amino-acid D-peptide derivative of human neuRL2 was chemically synthesized and purified commercially by Peptide Technologies Co ⁇ oration, MD, with a biotinyl-gly-gly spacer sequence inco ⁇ orated at its N- terminus:
  • the D-enantiomer of the human 69-amino-acid U-8 (4-72) was kindly synthesized by Dr. Ian Clark-Lewis (Institute of Medical and Veterinary Science,
  • the protein to be biotinylated 400 ug of D-U-8, in this case) in 39.2 ul of water was added to 8.8 ul IM NaHCO3 pH 8.6.
  • Bovine pancreatic S-protein (Sigma) was biotinylated and purified according to method given above.
  • Two different combinatorial bacteriophage peptide libraries were obtained. Both contain a randomized peptide epitope inserted in the same position of the pUI coat protein that, after removal of the signal peptide by processing, starts four amino acids from the N-terminus ( Figures 2 A and 2B).
  • One library contains a randomized hexapeptide epitope (Scott et al. (1990) Science 249:386; Figure 2B), while the other contains a randomized 15-mer peptide epitope ( Figure 2 A).
  • the bacteriophage were shaken out of the dish, and the dish was washed ten times with TBS/Tween. 400 ⁇ l of elution buffer (0.1M HCl adjusted to pH 2.2 with glycine, 1 mg/ml BSA) was added, and the dish rocked gently for 10 minutes. The eluate was pipetted into a tube containing 75 ⁇ l of IM Tris HCl pH. 9.1 to give a neutralized eluate. iv) Amplifying the bacteriophage eluate The neutralized eluate was concentrated on a Centricon 30-KDa ultrafilter, washed once with TBS, and collected in a total volume of 100 ⁇ l. Next, 100 ⁇ l of K91Kan terrific broth cells (see below) were added, and the tube was mixed gently and left at room temperature for 30 minutes. The terrific broth cells had been prepared by (i) inoculating a few mis of LB
  • the culture was poured into an Oak Ridge tube and centrifuged for 10 minutes at 5K ⁇ m.
  • the supernatant was poured into a second Oak Ridge tube and centrifuged at 10K ⁇ m for 10 minutes.
  • the supernatant was then poured into a fresh Oak Ridge tube containing 3 ml of 16.7% PEG/3.3M NaCl, mixed by inverting 100 times, and left on ice for at least 4 hours.
  • this mixture was centrifuged for 15 minutes at 10K ⁇ m to pellet bacteriophage.
  • the bacteriophage were then dissolved in 1 ml of TBS, transferred to a fresh tube, vortexed briefly, and centrifuged to pellet insoluble matter.
  • the supernatant was transferred to a second tube containing 150 ⁇ l of 16.7% PEG/3.3M NaCl. This was mixed by 100 inversions and placed in the refrigerator for at least 1 hour. It was centrifuged for 10 minutes to pellet the bacteriophage. The bacteriophage were dissolved in 200 ⁇ l TBS/0.02% NaN 3 , followed by vortexing and centrifuging. The supernatant, termed the amplified eluate 1, was removed and stored at 4 °C. This completed selection and amplification round 1. vi) Panning after pre-reacting bacteriophage with the biotinylated target (round 2)
  • DNA sequence analyses with purified bacteriophage single-stranded DNA templates used an 18-mer synthetic DNA primer: 5'-TGAATTTTCTGTATGAGG.
  • the priming site on the bacteriophage DNA is shown in Figure 2.
  • Protocol variant 3(P+LS) used a high concentration of biotinylated D-GRP bound to streptavidin on a plate as the target for all three rounds of affinity purification, enabling multivalent interactions between the bacteriophage, which displays about four copies of each peptide, and two or more target molecules bound to a single streptavidin.
  • the bacteriophage were eluted from the target with excess target instead of acid, thereby reducing background elution and increasing specificity (OTS.e.1 et al. (1992) Proteins: Struct. Fund. Genet. 14:509).
  • These protocol variants failed to isolate consensus motifs for D-GRP from the libraries (Table 1).
  • peptide ligands selected by large targets generally bind in the clefts of the targets, presumably because only clefts can form simultaneous contacts with several sides of a peptide ligand, thereby enabling a high affinity interaction.
  • Targets of less than 30 amino acids in length such as B-D-GRP and B-D-neuRL2
  • B-D-GRP and B-D-neuRL2 contain very small surfaces and are unlikely to contain clefts that may be necessary for high affinity interactions with ligands.
  • ligands have been successfully selected for two targets smaller than B-D-GRP and B-D-neuRL2 (Saggio et al. (1993) Biochem. J
  • Cyclic peptide ligands were inadvertently selected for binding to the biotinyl lysine group of a biotin-labeled protein (Saggio et al., supra), and peptides were selected for binding to a 9-amino acid peptide (Sasaki et al. (1996) Tetrahedron Let 37:85-88)
  • D-U-8(4-72) was chemically labeled with biotin to give B-D-U-8, and a portion of this was chemically cross-linked to give X-B-D-U-8 (supra).
  • Cross-linking was necessary to guarantee the existence of dimers under selection conditions, which necessarily use very low B-D-U-8 concentrations because of stringent washing conditions.
  • D-U.-8 had the expected mobility, and the biotin-labeling reaction did not significantly alter the mobility of D-Dl ⁇ -8.
  • the latter was not unexpected, because the biotinyl group (formular weight of 227) is only 3% as heavy as D-lL-8(4-72) ( formula weight of 8094), and an average of less than one biotin per D-lL-8(4-72) was expected.
  • X-B-D-1X-8 contained approximately one third dimer (formula weight of 16 200) and two thirds monomer by weight.
  • B-S-protein control target Since the bivalent B-MAb control target has the potential to form high affinity multivalent interactions with a bacteriophage (which displays about four copies of a peptide variant), it may have formed high affinity interactions with the selected bacteriophage. It was therefore not an ideal control target to test whether the selection and amplification protocols were able to select low affinity binders for drug targets.
  • An alternative control target, S-protein was therefore selected because this target is more like the drug targets in that it is small, monovalent, and only forms low affinity interactions with peptides selected from peptide libraries.
  • S-protein was chemically labeled with biotin to give B-S-protein.
  • Analysis of the labeled S-protein by protein electrophoresis showed that it had the expected mobility, with the biotin-labeling reaction not significantly altering the mobility of S-protein. This was not unexpected, because the biotinyl group (formular weight of 227) is only 2% as heavy as S-protein (formular weight of approximately 11 000).
  • the consensus sequence is therefore drawn to include these vector sequences, although evidence for their importance is not as strong as for the variable sequence of the 6-mers.
  • the first two positions of the consensus are not absolutely conserved, but they are always basic amino adds. The remaining positions are neutral amino acids, with trp and ile being absolutely conserved. This suggests that electrostatic and hydrophobic interactions are important for binding, and that the peptides bind to an acidic region of D-U-8.
  • the D-peptide enantiomers of the L-peptide sequences selected with B-D-LL-8 are candidate ligands for U-8.
  • the selected peptides recognize monomeric U-8. If they bind to a site on the monomer that is not disrupted by U-8 dimerization, it is possible that an U-8 dimer may bind two identical peptides. This would imply that a dimer of the selected peptide connected covalently with a spacer arm of appropriate length would have a much higher affinity for U-8 dimers than would a monomeric selected peptide.
  • Such a dimeric (or oligomeric) peptide ligand can be readily synthesized commercially by the multimeric antigenic peptide (MAP) method (Tam et al. (1988) PNAS 85:5409), and may be a more potent drug than the monomeric peptide ligand. It may also find utility in studies testing the effect of increased dimer to monomer ratios of U-8. In the future, it may be possible to deteirriine the peptide binding site on U-8 by alterations in the known NMR spectrum of U-8.
  • MAP multimeric antigenic
  • the diversity of the libraries could be increased by the simultaneous expression of greater numbers of peptides.
  • the record for the number of peptides displayed simultaneously has recently increased from the IO 8 variants in bacteriophage display libraries to 10 12 variants in polysome display libraries (Mattheakis et al., supra).
  • the binding affinities of selected and amplified ligands could be further increased by introducing repeated mutagenesis steps into the amplification process, thereby allowing true evolution of ligands (Mattheakis et al., supra). This has been done in RNA evolution experiments and can be readily adapted to peptide libraries (Lippman et al. (1993) Science 259:631).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention rend possible une approche dirigée puissante pour identifier les composés énantiosélectifs qui se fixent à des cibles biologiques. D'une façon générale, cette invention se rapporte, dans l'un de ses aspects, à un procédé pour identifier les composés qui interagissent avec une molécule cible (i) en plaçant une molécule de criblage en contact avec une banque de composés panachés, cette molécule de criblage comprenant une molécule cible solide ou l'énantiomère de cette molécule si la molécule cible est chirale; (ii) à sélectionner, dans cette banque de composés, les composés qui ont une interaction désirée avec la molécule cible; et (iii) à tester la capacité de l'énantiomère d'un composé sélectionné dans l'étape (ii) à interagir avec la molécule cible.
PCT/US1997/004176 1996-03-21 1997-03-21 Procede de criblage enantiomere et compositions pour ce procede WO1997035194A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25313/97A AU2531397A (en) 1996-03-21 1997-03-21 Enantiomeric screening process, and compositions therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62233896A 1996-03-21 1996-03-21
US08/622,338 1996-03-21

Publications (2)

Publication Number Publication Date
WO1997035194A2 true WO1997035194A2 (fr) 1997-09-25
WO1997035194A3 WO1997035194A3 (fr) 1997-12-18

Family

ID=24493816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004176 WO1997035194A2 (fr) 1996-03-21 1997-03-21 Procede de criblage enantiomere et compositions pour ce procede

Country Status (2)

Country Link
AU (1) AU2531397A (fr)
WO (1) WO1997035194A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153298A1 (fr) * 1999-02-17 2001-11-14 Carbozyme NT Ltd Echantillotheques combinatoires de glucides complexes, et procedes de fabrication et d'utilisation
FR2818648A1 (fr) * 2000-12-22 2002-06-28 Aventis Pasteur Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
WO2002051865A2 (fr) * 2000-12-22 2002-07-04 Aventis Pasteur Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
WO2002067860A2 (fr) * 2001-02-22 2002-09-06 The Scripps Research Institute Selection par dispositif d'affichage miroir
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
EP0882737B1 (fr) * 1992-06-05 2007-07-11 The Scripps Research Institute Protéine D liée et méthode pour identifier des composés qui modulent l'activité des récepteurs
WO2008116956A3 (fr) * 2007-03-27 2008-12-18 Proyecto Biomedicina Cima Sl Peptides capables de se fixer à l'interleukine 10 (il-10)
WO2017072222A1 (fr) 2015-10-30 2017-05-04 Janssen Vaccines & Prevention B.V. Conception basée sur une structure de ligands de protéine d

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009690A2 (fr) * 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1994016332A1 (fr) * 1993-01-13 1994-07-21 Yeda Research And Development Co. Ltd. Procede de criblage de polypeptides et de proteines non enzymatiques catalytiques
WO1995027072A1 (fr) * 1994-04-05 1995-10-12 Pharmagenics, Inc. Determination et identification de composes actifs dans une bibliotheque de composes
WO1996034879A1 (fr) * 1995-05-03 1996-11-07 Whitehead Institute For Biomedical Research Identification de ligands enantiomeres

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009690A2 (fr) * 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1994016332A1 (fr) * 1993-01-13 1994-07-21 Yeda Research And Development Co. Ltd. Procede de criblage de polypeptides et de proteines non enzymatiques catalytiques
WO1995027072A1 (fr) * 1994-04-05 1995-10-12 Pharmagenics, Inc. Determination et identification de composes actifs dans une bibliotheque de composes
WO1996034879A1 (fr) * 1995-05-03 1996-11-07 Whitehead Institute For Biomedical Research Identification de ligands enantiomeres

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882737B1 (fr) * 1992-06-05 2007-07-11 The Scripps Research Institute Protéine D liée et méthode pour identifier des composés qui modulent l'activité des récepteurs
EP1785726A1 (fr) * 1999-02-17 2007-05-16 Carbozyme NT Ltd Pharmacothèques de glucides complexes et procédés de fabrication et d'utilisation de celles-ci
EP1153298A1 (fr) * 1999-02-17 2001-11-14 Carbozyme NT Ltd Echantillotheques combinatoires de glucides complexes, et procedes de fabrication et d'utilisation
EP1153298A4 (fr) * 1999-02-17 2002-10-23 Glycominds Ltd Echantillotheques combinatoires de glucides complexes, et procedes de fabrication et d'utilisation
FR2818648A1 (fr) * 2000-12-22 2002-06-28 Aventis Pasteur Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
WO2002051865A2 (fr) * 2000-12-22 2002-07-04 Aventis Pasteur Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
WO2002051865A3 (fr) * 2000-12-22 2002-09-12 Aventis Pasteur Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
WO2002067860A2 (fr) * 2001-02-22 2002-09-06 The Scripps Research Institute Selection par dispositif d'affichage miroir
WO2002067860A3 (fr) * 2001-02-22 2003-02-20 Scripps Research Inst Selection par dispositif d'affichage miroir
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
CN101317093B (zh) * 2005-12-20 2012-09-19 夏普株式会社 用于结合配体的新的捕获试剂
WO2008116956A3 (fr) * 2007-03-27 2008-12-18 Proyecto Biomedicina Cima Sl Peptides capables de se fixer à l'interleukine 10 (il-10)
US8148334B2 (en) 2007-03-27 2012-04-03 Proyecto De Biomedicina Cima, S.L. Peptides with capacity for binding with interleukine 10 (IL-10)
WO2017072222A1 (fr) 2015-10-30 2017-05-04 Janssen Vaccines & Prevention B.V. Conception basée sur une structure de ligands de protéine d
US11322228B2 (en) 2015-10-30 2022-05-03 Janssen Vaccines & Prevention B.V. Structure based design of d-protein ligands

Also Published As

Publication number Publication date
WO1997035194A3 (fr) 1997-12-18
AU2531397A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
Hufton et al. Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands
US6031071A (en) Methods of generating novel peptides
JP3447731B2 (ja) 改良された顕示ファージ
US7772189B2 (en) Phage displayed cell binding peptides
JP2000505306A (ja) ２つまたはそれ以上の相互作用性（ポリ）ペプチドをコードする核酸配列の新規同定方法
US20080032896A1 (en) Methods for identifying compounds that bind to a target
US20150344875A1 (en) Isolating Biological Modulators from Biodiverse Gene Fragment Libraries
JPH06504666A (ja) ランダム化ペプチドの表面発現ライブラリー
US20020081570A1 (en) System to detect protein-protein interactions
KR20080039869A (ko) 신규한 파지 디스플레이 방법
US20120270808A1 (en) Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
WO2000023465A9 (fr) Procedes et reactifs permettant d"isoler des peptides actifs au plan biologique
Cesareni et al. Phage displayed peptide libraries
Lunder et al. Comparison of bacterial and phage display peptide libraries in search of target-binding motif
CA2545590C (fr) Mimetiques de boucle en epingle a cheveux-beta fixees a une matrice et leur utilisation dans l'expression phagique
WO1997035194A2 (fr) Procede de criblage enantiomere et compositions pour ce procede
CA2383186A1 (fr) Technique d'identification de fonction de gene par l'utilisation de petites sondes moleculaires
Caparon et al. Analysis of novel streptavidin-binding peptides, identified using a phage display library, shows that amino acids external to a perfectly conserved consensus sequence and to the presented peptides contribute to binding
US7175983B2 (en) Adapter-directed display systems
US20030119062A1 (en) Detection of differential expression of protein using gel-free proteomics
Li et al. Mutations in the N-terminus of the major coat protein (pVIII, gp8) of filamentous bacteriophage affect infectivity
JP3386210B2 (ja) 組換え及び合成ペプチドの製造法並びにそれらの用途
Cardellini et al. Identification of peptides mimicking the ligands of proteins phosphorylated by protein kinase CK2
Ku A combinatorial approach towards molecular recognition
EP1333096A1 (fr) Procedes pour identifier la fonction du gene par l'expression phagique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: JP

Ref document number: 97533582

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载